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ABSTRACT OF THE DISSERTATION
The Regulation of Extracellular Amyloid-β Levels by Ionotropic Glutamatergic Transmission in
an Alzheimer’s Disease Mouse Model
by
Jane Cecelia Hettinger
Doctor of Philosophy in Biology and Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2017
Professor John R Cirrito, Chair

Brain extracellular concentration of the peptide amyloid-β (Aβ) is a major contributor to
Alzheimer’s disease (AD) pathogenesis. High Aβ levels in the extracellular space precipitate
aggregation of the peptide into soluble and insoluble toxic species. This process begins decades
before cognitive impairment and triggers the cascade of pathology that eventually leads to AD.
Synaptic activity is key to the regulation of extracellular Aβ levels. Presynaptic activity drives
the production of Aβ, while postsynaptic receptor activation exhibits more nuanced regulation.
For example, high levels of NMDA receptor (NMDA-R) activation have been shown to decrease
Aβ production through the extracellular signal-regulated kinase (ERK). The studies outlined in
this document sought to determine the pathways by which Aβ levels are influenced by NMDARs as well as the other major ionotropic glutamate receptors, AMPA-Rs. We found that NMDARs activate ERK and decrease Aβ production through a pathway non-specific to NMDA-R
subtype or ERK isoform and that does not rely on calcium/calmodulin-dependent protein kinase
II (CaMKII), protein kinase A (PKA), or protein kinase C (PKC) signaling. We also found that
vii

though basal AMPA-R activity increases Aβ levels, evoked activation of AMPA-Rs reduces
extracellular Aβ through distinct NMDA-R-dependent and independent pathways. Unexpectedly,
NMDA-R-independent AMPA-R regulation decreases Aβ levels by reducing its half-life in the
extracellular fluid. Because previous studies describe synaptic activity-mediated Aβ regulation
through altered production, this finding presents a novel link between synaptic transmission and
Aβ clearance. The work described here aims to explore the mechanisms by which normal brain
activity influences Aβ homeostasis in an effort to more fully understand AD pathogenesis.

viii

EPIGRAPH

“My strength lies solely in my tenacity.”
- Louis Pasteur
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Chapter 1
Introduction and Perspective

1

Alzheimer’s Disease
Alzheimer’s disease (AD) accounts for 60 to 80 percent of dementia, affecting an
estimated 5.4 million Americans as of 2016 (www.alz.org). The prevalence of AD is only
expected to grow due to an aging population, with estimates projecting 13.8 million affected
Americans by 2050 barring significant scientific progress. The cost of dementia healthcare is
overwhelming and untenable; 2016 healthcare costs are estimated to be $236 billion even
without incorporating secondary costs to care providers. Out of the top ten causes of death, AD is
the only disease without a cure, prevention, or even a way to slow disease progression. There are
currently only five FDA-approved pharmaceuticals for AD, and all are designed to temporarily
ease symptoms. Clearly, there is an exigent need for AD therapeutic development.
In the ten-year period between 2002 and 2012, over 400 AD clinical trials were
performed with a disheartening 0.4% rate of success (Cummings et al., 2014). A variety of
factors have contributed to the failure of these trials, including a lack of clear and sensitive
outcome criteria, complications with drug delivery, and the protracted trial length required for
such studies (Becker 2008). A further obstacle to progress is that the presentation of AD
symptomatology occurs at least 10-20 years after disease pathogenesis (Morris and Price, 2001).
On a positive note, recent advances have characterized AD biomarkers that now allow clinicians
and researchers to quantify presymptomatic AD pathology.
The Alzheimer’s diseased brain exhibits extensive neuronal death and synaptic loss
throughout the cortex as well as two major lesions: amyloid plaques and neurofibrillary tangles.
Amyloid plaques are composed of the peptide amyloid-β (Aβ) aggregated within the
extracellular space of the brain. Aβ that has folded into traditional amyloid β-sheet secondary
2

structures are called fibrillar plaques, whereas diffuse plaques are composed amorphous deposits
of Aβ. Fibrillar plaques, also called neuritic plaques, are usually surrounded by a corona of
dystrophic neurites and activated glia. Neurofibrillary tangles, on the other hand, are intracellular
deposits of hyperphosphorylated tau. Normally, tau serves as a tubulin binding protein that
stabilizes microtubules. In AD, however, tau is hyperphosphorylated, dissociates from
microtubules, and accumulates as paired helical filaments. Cognitive impairment is highly
correlated with the presence of neurofibrillary tangles, though the same is not true of amyloid
plaques (Nagy et al., 1995; Guillozet et al., 2003; Bennett et al., 2004; Mocanu et al., 2008).
These two AD pathologies share a complex relationship that is still an active area of research.
The presence of Aβ plaques appears to drive tau pathology. Tau pathology is not seen in the
neocortex without coexisting Aβ pathology, though amyloid plaques can occur without the
presence of tau (Price and Morris, 1999). In addition, tau pathology is greatly exaggerated in
mice with mutant human tau following injection of Aβ fibrils (Götz et al., 2001). In cognitivelyimpaired transgenic mice with both human Aβ and tau, however, the removal of Aβ pathology is
not sufficient to ameliorate cognitive loss (Oddo et al., 2006). Furthermore, tau aggregation can
directly cause neurotoxicity and synaptic loss in mouse models with mutant tau, while amyloidonly AD mouse models do not exhibit neurodegeneration (Mocanu et al., 2008). It appears that
Aβ is necessary to initiate disease pathology but not sufficient to explain the entirety of AD
pathology or symptomology. The relative importance of both Aβ and tau aggregates in AD
progression continues to be hotly debated, a topic that I will discuss in greater detail below.
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Amyloid Cascade Hypothesis
Amyloid-β (Aβ) was first discovered by isolating and purifying the principal component
of cerebral amyloid angiopathy (CAA) and then amyloid plaques from Alzheimer’s disease and
Down’s syndrome brains (Glenner and Wong, 1984; Masters et al., 1985). In 1987, genetic
analysis revealed the amino acid sequence of Aβ, isolated the amyloid precursor protein (APP)
from which Aβ is cleaved, and mapped APP to chromosome 21 (Goldgaber et al., 1987; Tanzi et
al., 1987; Tanzi, 2012). After the first causative early onset-familial AD (EO-FAD) mutation in
APP was discovered in 1991 (Goate et al., 1991), many began to view Aβ as the initiating factor
in AD pathology, a concept that was presented by Hardy & Higgins (1992) as the amyloid
cascade hypothesis. In the 15 years since this seminal paper was published, mountains of data
has been generated in support and against this hypothesis, making it arguably the most
controversial topic in AD research today.
One of the strongest arguments bolstering the amyloid cascade hypothesis is made using
the genetic data gathered from AD patients, particularly from those patients with EO-FAD. EOFAD is extremely rare and numbers regarding its prevalence are vague. Approximately 1-5% of
all AD cases are thought to be early onset, both familial and sporadic (alzforum.org). EO-FAD is
characterized by an autosomal dominant inheritance of fully penetrant mutations in any one of
three genes: APP, presenilin-1 (PSEN1), and presenilin-2 (PSEN2) (for review see: Tanzi, 2012).
Importantly for the amyloid cascade hypothesis, inheritance of any of the approximately 225
mutations identified for EO-FAD (http://www.molgen.ua.ac.be/ADMutations) causes AD by
influencing Aβ aggregation. In these rare cases, Aβ clearly drives pathology, which begins with
the appearance of fibrillar amyloid plaques later followed by tau pathology and neuronal loss
(Musiek and Holtzman, 2015).
4

Though EO-FAD genes clearly indicate Aβ as a causative factor in AD, late-onset AD
(LOAD) compromises the vast majority of AD cases. LOAD susceptibility is much more
complex than EO-FAD and includes a myriad of genetic risk factors as well as environmental
influences. Currently, numerous large, worldwide, case-controlled genome-wide association
studies (GWAS) have identified 12 genes associated with LOAD. Only one of these gene
variants, however, is an established risk factor with a strong association with AD – the ε4 allele
of the apolipoprotein gene (APOE; Strittmatter et al., 1993; Tanzi, 2012). Though APOE ε4 is
not a causative factor in AD, one copy of the allele increases the risk of 4-fold and two copies
increase the risk 12-fold (Corder et al., 1993). ApoE has a multitude of roles in the CNS,
primarily involving lipid metabolism and transport. Its relevance to AD, apoE has shown to bind
Aβ directly and studies have found that earlier and greater Aβ deposition occurs in individuals
with two ε4 alleles. Furthermore, studies using transgenic Alzheimer mouse models have found
that apoE alleles can influence the amount and structure of Aβ deposits in the brain (Holtzman et
al., 2000, 2011). As with EO-FAD, the genetic factors for LOAD yield strong evidence that Aβ
has an important and potentially causative role in AD.
Despite these strong genetic arguments for the amyloid cascade hypothesis, there remain
a number of concerns regarding the importance of Aβ and its initiating role in pathology. The
first argument against the hypothesis is the lack of correlation between the amount of Aβ
deposition and neuronal loss and clinical symptoms, both temporally and spatially. Where Aβ
plaques begin to form in the precuneus and frontal lobes, neuronal loss occurs in the entorhinal
cortex and hippocampus (Braak and Braak, 1991). Tau pathology, on the other hand, overlaps
with neuronal loss and correlates more strongly with cognitive impairment (Arriagada et al.,
1992; Nagy et al., 1995; Mocanu et al., 2008). The lack of correlation between plaque load and
5

AD symptoms has been made clear following the unfortunate failure of clinical trials that have
targeted Aβ. Notable is the Elan AN1792 active Aβ immunization study in which amyloid
plaques were successfully cleared from the brains of AD patients without a resulting
improvement in cognition (Holmes et al., 2008).
Although these findings certainly cast doubt on the concept that Aβ causes AD
symptomology on its own, there is still a strong argument for the importance of Aβ in AD. While
overall amyloid burden might not correlate with cognitive impairment, a number of studies
suggest that it is soluble oligomeric Aβ species that are neurotoxic and cause synaptic
dysfunction, not monomeric Aβ or fibrillar amyloid plaques (De Felice et al., 2007; Lacor et al.,
2007; Benilova et al., 2012; Talantova et al., 2013). Oligomer quantification is difficult, but it
could be that the number of oligomers has a stronger correlation with cognitive decline than
plaque load. Moreover, evidence suggests that Aβ-related pathology has the ability to initiate
downstream AD pathology. Mice generated with both mutant human APP and mutant human tau
show increased formation of tau tangles compared to mice that only express human tau, though
the number of plaques is unchanged (Lewis et al., 2001). Furthermore, human biomarker data
shows that Aβ pathology precedes alterations in tau pathology by years (Bateman et al., 2012). In
light of the genetic data previously described, the fact that Aβ deposition occurs before other AD
pathology suggests that Aβ production and aggregation is the causative, initiating factor of AD
pathogenesis. Initial clinical trials targeted Aβ using participants within the later stages of AD
who already exhibit cognitive decline. By this point in the disease progression, Aβ has already
initiated an entire cascade of downstream pathology that will likely not be ameliorated once Aβ
is removed. Thus, when targeting Aβ, the earlier, the better to intercede prior to substantial
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pathology, cell loss, or brain damage. Naturally, the difficulty with this notion is identifying and
recruiting asymptomatic participants who may or may not develop AD.
One ongoing study, the Dominantly Inherited Alzheimer Network (DIAN) treatment trial,
seeks to address this issue by recruiting participants from OE-FAD families who carry a
causative mutation and beginning anti-amyloid treatment early in the pathological cascade
(Bateman et al., 2012). Another ongoing trial, the Anti-Amyloid Treatment in Asymptomatic
Alzheimer’s Disease (A4) study, is using cognitively normal, older participants who show
evidence of amyloid pathology with the same concept of targeting Aβ early to prevent further
AD pathology and cognitive decline (https://clinicaltrials.gov). Results from these studies will
give insight into the amyloid hypothesis, and will particularly indicate the viability of
therapeutically targeting Aβ.
The amyloid cascade hypothesis has stood as one of the fundamental concepts
guiding Alzheimer’s research since its conception in 1992(Hardy and Higgins, 1992; Hardy and
Selkoe, 2002; Selkoe and Hardy, 2016). Since this time, we have found that AD comprises a
complex confusion of pathological events, such as tau phosphorylation, neuroinflammation,
mitochondrial damage, synaptic dysfunction, oxidative stress, and neuronal loss (Musiek and
Holtzman, 2015). Though Aβ is clearly not acting on its own to bring about the changes
observed in the AD brain, neither its importance in AD pathogenesis nor its potential as an AD
therapeutic can be denied.
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Amyloid Precursor Protein Processing
Amyloid-β is a 37-43 amino acid peptide produced from the cleavage of the amyloid
precursor protein (APP). The APP family of proteins, which includes the APP-like protein 1 and
2 (APLP1, 2), are type 1 membrane proteins with large extracellular domain and short
cytoplasmic tails (Zheng et al., 2011). These APLPs do not produce Aβ; though the family is
highly conserved, APLPs lack the Aβ sequence. While the specific physiological function of
APP is not known, the fact that Aβ is not conserved suggests that it is unrelated to APP’s
primary function. APP is ubiquitously expressed throughout the body and is highly enriched in
the brain. Within the CNS, APP is strongly expressed in neurons, with little to no expression in
non-neuronal cell types (Guo et al., 2012). Once APP is produced, it leaves the ER and is sorted
through the trans-Golgi network and trafficked to the plasma membrane. APP is then internalized
and trafficked through the endocytic pathway to either be recycled back to the membrane or
degraded in the lysosome (Thinakaran and Koo, 2008). When APP reaches the membrane, it is
subject to processing through the amyloidogenic or non-amyloidogenic pathways.
Amyloidogenic Pathway
Amyloidogenic APP processing occurs when APP is sequentially cleaved by β-and γsecretases to produce the Aβ peptide. APP is first cleaved by β-secretase, resulting in the
shedding of most of the ectodomain, a fragment called sAPPβ. The resulting C-terminal,
membrane-bound fragment is termed C99 or β-CTF. C99 can then be cleaved by γ-secretase to
produce Aβ and the APP intracellular domain (AICD; Haass et al., 2012). Cleavage by βsecretase is the rate-limiting process in Aβ production. The enzyme within β-secretase
responsible for cleaving at the β-site, a transmembrane aspartyl protease, has been identified and
8

named BACE1 (β-site APP cleaving enzyme). BACE1 is optimally active in acidic
environments, such as found in the lumen of endosomes, suggesting that BACE1 preferentially
cleaves APP once endocytosed (Turner et al., 2003; Haass et al., 2012). Given its role in
producing Aβ, BACE1 is clearly an attractive target for drug development. Many BACE
inhibitors have been developed, and there are clinical trials ongoing whose outcomes are yet to
be seen (www.alzforum.org).
The γ-secretase complex is composed of four subunits: presenilin-1 (PS1), presenilin-2
(PS2), nicastrin, APH-1, and PEN-2. Presenilin-1 and -2 make up the catalytic domain of the
complex. γ-Secretase is a sloppy proteinase and cleaves at multiple sites within the
transmembrane domain of Aβ between amino acids 37 and 43, producing different Aβ species
(Thinakaran and Koo, 2008). Most of the Aβ produced is 40 residues in length (Aβ40), but the
longer Aβ42 residue is more prone to aggregation and thus the major component of amyloid
plaques (Miller et al., 1993). Mature γ-secretase is principally located at the plasma membrane
and in endosomes. Interestingly, of the three genes with mutations linked to EO-FAD, two
involve the γ-secretase complex. Mutations in PS-1 and -2 alter cleavage site specificity, leading
to the preferential production of Aβ42 over Aβ40. The resulting increased Aβ42/Aβ40 ratio leads to
increased amyloid aggregation.
Of all the secretases, γ-secretase has proven to be the most tractable target for drug
development. There have been multiple effective γ-secretase inhibitors (GSIs) developed that
decrease Aβ production in both mice and humans, though toxicity has been an issue. Enthusiasm
for GSI clinical trials has been low following the dramatic failure of Eli Lilly’s phase III
semagacestat in which there were both significant toxic effects as well as clinical worsening
(Doody et al., 2013). To date, all GSI clinical trials have been stopped due to mechanism-based
9

toxicities. A new class of drug targeting γ-secretase is now in development. Gamma-secretase
modulators (GSMs) modify the activity of the enzyme so that less Aβ42 is produced without
changing the processing of other γ-secretase substrates. Currently, these drugs are still only
tested in animal models in an effort to combine potency with safe drug-like properties but are
expected to move into proof-of-mechanism human clinical trials (Bursavich et al., 2016).
As mentioned above, BACE1’s increased activity in low pH environments suggests that
the amyloidogenic processing of Aβ occurs within endosomes. Indeed, multiple groups have
found that clathrin-mediated endocytosis of APP is essential for Aβ generation (Koo and
Squazzo, 1994; Cirrito et al., 2008). Further, Aβ elimination is not affected when endocytosis is
blocked. Once Aβ is cleaved from APP, it is released into the endosomal lumen and then
released into the extracellular space following exocytosis. Once in the extracellular space, Aβ
can begin to aggregate. Importantly, greater extracellular concentrations of Aβ result in elevated
aggregation and vice versa (Meyer-Luehmann et al., 2003).
Non-amyloidogenic Pathway
The production of Aβ can be precluded if APP is cleaved by α-secretase instead of βsecretase. This non-amyloidogenic processing occurs because α-secretase cleaves APP within the
Aβ domain, resulting in the large ectodomain sAPPα and the membrane-tethered C83 or α-CTF.
C83 can then be cleaved by γ-secretase to produce the 3kDa p3 and AICD, similarly to C99
(Zheng et al., 2011). There are several zinc metalloproteinases, members of the “a disintegrin
and metalloproteinase” family (ADAM), that can function as α-secretases; however, ADAM10
has been identified as the primary α-secretase in neurons (Kuhn et al., 2010). Nonamyloidogenic APP processing predominantly occurs at the plasma membrane (Haass et al.,
10

2012). Studies that overexpress or knockout BACE1 have found that there may be substrate
competition between α- and β-secretase such that enhancing the amyloidogenic pathway
depresses the non-amyloidogenic pathway and vice versa (Turner et al., 2003). The therapeutic
implication of this fact is that increasing α-secretase activity and the non-amyloidogenic pathway
leads to decreased Aβ production. In support of this concept, overexpression of ADAM10 in an
amyloidosis mouse model results in decreased amyloid pathology (Postina et al., 2004; De
Strooper et al., 2010). Despite this, α-secretase is not an ideal therapeutic target due to a high
degree of redundancy between the ADAM proteases, making direct activators difficult to
develop. However, drugs that indirectly activate α-secretase by targeting a regulator of its
activity show more promise (De Strooper et al., 2010).

Synaptic Activity and Aβ Production
Production of Aβ is influenced by a number of regulators, chief among them being
synaptic activity. In 2003, Kamenetz et al. tested the role that neuronal activity plays in APP
processing by using pharmacology to increase or decrease activity in organotypic hippocampal
slices from an AD mouse model and measuring the Aβ levels in the medium. When activity was
decreased, levels of both Aβ40 and Aβ42 were reduced. Conversely, levels were elevated with
enhanced neuronal activity. Further experimentation found that levels of C99 (β-CTF) were
increased with increased activity, suggesting that β-secretase is involved in the elevation of Aβ
levels.
Following this intriguing paper, Cirrito et al. (2005) used in vivo microdialysis to test the
relationship between synaptic activity and Aβ production in awake, freely moving AD mouse
11

models. Both pharmacological manipulators of activity (tetrodotoxin and tetanus toxin to
decrease activity, picrotoxin to increase) and perforant pathway electrical stimulation were used
and interstitial fluid (ISF) Aβ levels were measured. As in the study by Kamenetz et al., synaptic
activity was determined to drive Aβ generation. The study further identified that synaptic vesicle
exocytosis alone, even without an action potential, was enough to increase Aβ levels. Cirrito et
al. (2005) proposed that synaptic vesicle membrane recycling that occurs during synaptic activity
is linked to APP endocytosis, which, as previously discussed, is known to increase Aβ
production and release (Koo and Squazzo, 1994; Cirrito et al., 2008). In fact, inhibiting clathrinmediated endocytosis with a dominant negative version of dynamin, an endocytosis GTPase,
completely blocked the effect of synaptic activity on Aβ levels. The opposite is not true;
inhibiting action potentials only partially blocks the effect of endocytosis, meaning that there is a
percentage of Aβ produced through endocytosis not caused by synaptic activity (Cirrito et al.,
2008). In line with these findings, Das et al. (2013) were able to visualize APP and BACE1
trafficking in cultured neurons to show that synaptic activity causes the convergence of APP and
BACE1 in recycling endosomes, resulting in increased Aβ production.
Further studies have gone on to test the relationship between synaptic activity and Aβ
generation in more physiological settings. For example, endogenous neuronal activity was
induced in the barrel cortex through manual vibrissal stimulation, resulting in localized increases
in ISF Aβ levels (Bero et al., 2011). Similarly, unilateral ablation of whiskers lead to depressed
activity in the corresponding barrel cortices and thus reduced plaque load (Tampellini et al.,
2010a). Another piece of physiological evidence comes from studies showing that Aβ levels in
the ISF follow a diurnal pattern with highest levels during periods of wakefulness and lowest
levels during sleep. Furthermore, acute sleep deprivation resulted in increased ISF Aβ and
12

chronic sleep deprivation lead to increased Aβ plaque deposition (Kang et al., 2009). These
results were supported and furthered by a recent study showing that disruption of slow wave
activity, which occurs during non-REM sleep and represents decreased synaptic activity,
increased Aβ levels in the cerebrospinal fluid of cognitively normal human participants (Ju et al.,
2017).
Observations in human patients support synaptic activity-dependent Aβ generation.
Temporal lobe tissue removed from non-demented epileptic patients was found to have a greater
incidence of senile plaques than non-epileptic autopsy controls, indicating that elevated synaptic
activity can drive amyloid pathology (Mackenzie and Miller, 1994). Studies using both positron
emission topography (PET) and functional magnetic resonance imaging (fMRI) have identified a
network of cortical regions that are active during rest, when the participants are not actively
performing a task, termed the default mode network (Raichle et al., 2001). Revealingly, this
network of brain regions that maintain a high level of synaptic activity closely correlate with the
pattern of amyloid deposition in AD brains (Buckner et al., 2005). Buckner et al. (2009)
continued on to identify that these default mode regions are actually part of a map of cortical
hubs, areas that provide nodes of convergence for interconnecting and distinct systems through
high levels of connectivity. These hubs maintain high levels of activity continuously regardless
of task state. The study found that high levels of connectivity in the brain, i.e., hubs, strongly
correlate with levels of Aβ deposition (Buckner et al., 2009). Finally, a study using patients
undergoing intracranial monitoring following acute brain injury was able to demonstrate that, as
in mice, human brain ISF Aβ concentrations correlate with neuronal function (Brody et al.,
2008).
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Post-synaptic Signaling and Aβ Production
Synaptic activity regulates of Aβ production through increased endocytosis at the
presynaptic membrane, as discussed previously. In addition to this presynaptic pathway of
regulation, synaptic activity can also modulate APP processing and Aβ production through
postsynaptic receptor signaling. This modulation can occur in opposition to presynapticdependent Aβ release, resulting in decreased Aβ production. Compared to the presynaptic
pathway discussed before, postsynaptic regulation is complex and frequently involves multiple
signaling events.
Agonists for muscarinic acetylcholine receptors (mAChRs) have been used to ameliorate
cognitive impairment in humans for many years. This limited clinical value has inspired a
number of studies investigating the relationship between mAChRs and AD pathology, including
Aβ production. These studies found that M1 mAChR stimulation increased the production of
sAPPα, indicating increased non-amyloidogenic processing of APP (Fisher, 2012). M1 AChRs
act on APP processing through protein kinase C (PKC) activation, which activates ADAM17 in
turn. Blocking mAChR signaling either by chemically lesioning the cholinergic nucleus basalis
magnocellularis or by using a specific inhibitor decreased Aβ plaque load in an AD mouse
model. mAChR inhibition both activated α-secretase and inhibited BACE1 (Fisher, 2012).
Furthermore, deletion of M1 mAChRs enhanced cognitive impairment and resulted in greater
plaque load (Davis et al., 2010).
Throughout the brain, glutamate serves as the primary excitatory neurotransmitter. There
are multiple subtypes of glutamate receptors, both ionotropic and metabotropic. Within the
context of AD, the ionotropic N-methyl-D-aspartate (NMDA) receptor is the most studied due to
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its pivotal role in mediating long-term potentiation (LTP), the cellular correlate for memory.
There is a great deal of evidence linking Aβ to NMDA-R dysfunction (for review see Zhang et
al., 2016), but there are a number of studies that describe a reciprocal relationship in which
NMDA-R signaling affects APP processing and Aβ production. Low concentrations of NMDA
applied to primary cortical neurons promoted Aβ release via increased BACE processing (Lesné
et al., 2005). A different group, however, found that an acute, sublethal pulse of NMDA
treatment in vitro resulted in increased trafficking of ADAM10 to the postsynaptic membrane
through an interaction with the synapse-associated protein97 (SAP97), which would increase
non-amyloidogenic APP processing (Marcello et al., 2007). In concurrence with this study, Hoey
et al. (2009) found that NMDA receptor signaling increases C83 (CTF-α) by 2.5-fold, indicating
an increase in α-secretase APP cleavage. Indeed, these effects were blocked by treatment with an
α-secretase inhibitor (Hoey et al., 2009). In 2011, our group published a paper addressing these
incongruent findings using in vivo microdialysis to address the question in a more physiological
context. A mouse model of AD was treated with a range of NMDA concentrations. We found
that the effect of NMDA on Aβ levels in the ISF is dependent on concentration such that low
concentrations of NMDA increase ISF Aβ while higher doses appear to do the opposite. Further
experiments showed that the increase in Aβ found with low levels of NMDA activation is
dependent on action potentials in a manner identical to previous findings that presynaptic activity
drives Aβ (Cirrito et al., 2005b; Verges et al., 2011), though higher levels of NMDA do not
require synaptic activity to affect Aβ. Instead, high doses of NMDA lead to calcium-dependent
activation of extracellular regulated kinase (ERK), which initiates a signaling cascade that
promotes α-secretase activity. Thus, this study reconciled previous conflicting reports on
NMDA-Rs relationship to Aβ production by positing that the end result of NMDA-R activation
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depends on the level of ERK activation (Verges et al., 2011). The pathway through which ERK
ultimately acts on α-secretase activity is unknown and will be addressed later in this document.
Another group of glutamatergic postsynaptic receptor shown to regulate Aβ production is
the metabotropic glutamate receptors (mGluRs), although its actions on Aβ are more complex.
Broad mGluR activation in primary cultures and in slices resulted in increased sAPPα; however,
a more selective agonism of the mGluR subtype mGluR5 has the opposite effect, increasing Aβ
production. This indicates that specific receptor subtypes have opposing effects on Aβ
generation. In fact, activation of postsynaptic Group I mGluRs was found to produce Aβ40
release while Group II mGluR stimulation triggered Aβ42 production (Kim et al., 2010). In
support of these results, the genetic deletion of mGluR5 in AD mouse models resulted in
significantly decreased Aβ aggregation and plaque number along with improved cognition
(Hamilton et al., 2014).
The final postsynaptic receptor to discuss is the serotonin (5-HT) receptor. Using in vivo
microdialysis to treat Alzheimer’s mouse models of AD with selective serotonin reuptake
inhibitors (SSRIs) that increase serotonergic signaling, drugs that are commonly used to treat
depression, lead to decrease ISF Aβ levels, as does direct treatment with serotonin (Cirrito et al.,
2011). Like the effect of NMDA-Rs on Aβ, this serotonergic effect is dependent on ERK
signaling and increased α-secretase activity. This pathway appears to rely on the activation of the
5-HT5R, 5-HT6R, and 5-HT7R subtypes, which are all coupled to Gs-signaling and activate
protein kinase A (PKA; Fisher et al., 2016). Chronic SSRI administration to AD mouse models
for four months decreased both soluble and insoluble Aβ levels in brain lysates and decreased
plaque load. These findings were supported by similar findings in humans. Cognitively normal
participants with a history of antidepressant use underwent PET Aβ imaging, a method used to
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quantify cortical plaque load. Compared to participants with no antidepressant usage reported,
treated participants exhibited much less cortical amyloid (approximately half). Given that SSRIs
are FDA-approved and well-tolerated, the authors of this study propose that SSRIs could make
an ideal preventative anti-Aβ therapy (Cirrito et al., 2011; Sheline et al., 2014)

Amyloid-β Clearance
As mentioned previously, the steady-state concentration in the extracellular space is a
key determinant in the propensity of monomeric Aβ to begin the toxic process of aggregation
(Meyer-Luehmann et al., 2003). While much of the research on Aβ focuses on its production,
increased steady-state Aβ levels spring from an imbalance between production and clearance. In
fact, evidence is beginning to indicate that impaired Aβ clearance may be a key factor in both
EO-FAD and LOAD. In a study by Mawuenyega et al. (2010), used a technique called stable
isotope labeling kinetics (SILK) to compare the kinetics of Aβ turnover in the CSF of
participants with symptomatic LOAD to cognitively normal controls. Briefly, participants were
infused with a non-radioactive isotope-labeled leucine, which is soon incorporated into most
newly made leucine-containing proteins. CSF samples are collected from the participants
through lumbar puncture hourly and analyzed for labeled Aβ using tandem mass spectrometry.
Both production and clearance kinetics can be calculated using this method, making it a powerful
tool. Surprisingly, the researchers found a 30% impairment in the clearance of both Aβ40 and
Aβ42 in the Alzheimer’s patients compared to controls, though no change in production was
measured (Mawuenyega et al., 2010). The same technique was used in EO-FAD participants
carrying PSEN mutations. Compared to sibling noncarrier controls, the PSEN mutation carriers
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exhibited a 24% increase in CNS Aβ40 and Aβ42, suggesting that EO-FAD and LOAD have
different disease mechanisms (Potter et al., 2013).
The prominence of impaired clearance in LOAD is supported by genetic evidence. The
strongest risk factor for LOAD, the apoE ε4 allele, is thought to involve alterations in Aβ
clearance, although the exact mechanism behind apoE’s link to AD remains controversial (Bell
et al., 2007). In addition to apoE, GWAS have identified several other genetic variants that
increase the risk of LOAD. At least two of these gene, PICALM and CLU, are thought to be
related to Aβ clearance (De Strooper and Karran, 2016). Aβ clearance is a complex process
mediated through multiple processes and molecular players. Below I will outline the four major
pathways responsible for clearing Aβ from the extracellular space: proteolytic degradation,
transport into the blood or lymph, bulk flow of the CSF, and cellular uptake and subsequent
intracellular degradation.
Aβ Transport across the BBB
By comparing Aβ levels in time-matched arterial, peripheral venous, and central venous
blood samples from human participants, Roberts et al. (2014) were able to calculate the net
transport of Aβ across a capillary bed from the CNS to the plasma. Based on these findings, the
researchers conservatively estimated that approximately 25% of Aβ clearance results from direct
transport of Aβ across the BBB (Roberts et al., 2014). Movement of Aβ across the BBB is
primarily mediated by two receptor proteins: the low-density lipoprotein receptor related protein1 (LRP1) and the receptor for advanced glycation end products (RAGE). LRP1 is associated
with Aβ efflux from the brain into the periphery, whereas RAGE is implicated in influx.

18

LRP1 is a member of the LDL receptor family involved in signal transduction that has
been shown to interact with Aβ. LRP1 is highly expressed in neurons, glia, and vascular cells in
the brain; notably, its expression within brain capillaries is reduced during normal aging and in
AD brains (Kanekiyo and Bu, 2014). It is thought that LRP1 directly binds to Aβ in the ISF and
allows Aβ to be transcytosed across the BBB into the bloodstream (Deane et al., 2004; Bell et al.,
2007). Inhibiting LRP1 function with either antagonists or inhibiting antibodies significantly
impairs Aβ clearance and deletion of LRP1 in vascular smooth muscle cells exacerbated Aβ
deposition (Kanekiyo et al., 2012). LRP1 preferentially binds Aβ40 over the more aggregationprone Aβ42 as well as a more amyloidogenic mutant Aβ, suggesting that fibrillogenic Aβ may be
more difficult to remove from the ISF (Tanzi et al., 2004). The ATP-binding cassette transporter
p-glycoprotein (Pgp, also known as ABCB1) has also been implicated in Aβ efflux. Acute
inhibition of Pgp in an Alzheimer’s mouse model resulted in a 30% increase in ISF Aβ levels.
Furthermore, Pgp-null mice show decreased Aβ transport across the BBB and, like LRP-1, Aβ40
is preferentially targeted. Pgp deletion leads to increased Aβ deposition in a mouse model
(Cirrito et al., 2005a).
Opposing the actions of LRP1 and Pgp, RAGE actively transports soluble Aβ from the
bloodstream back into interstitium. Transgenic APP models and AD brains exhibit upregulated
RAGE, implicating it as a physiologically relevant player in AD pathology (Deane et al., 2004).
ISF Bulk Flow
Aβ residing in the ISF can be cleared from the brain alongside other ISF solutes. The ISF
is the fluid found in the miniscule gaps between cells in the brain, occupying the extracellular
space that contacts the basement membranes of the capillaries making up the BBB. The ISF
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makes up approximately 15-20% of volume of an adult brain (Lei et al., 2016). Following tracers
injected into the brain, researchers have identified a bulk flow of ISF along the basement
membranes of capillaries and arteries that relies on diffusion. This pathway, the perivascular
drainage pathway, eventually moves ISF towards the cervical lymph nodes. Drainage along this
pathway is estimated to occur at a rate of 0.11-0.29µL/minute/g of brain tissue. This movement
is driven by pulsations of intracranial arteries (Weller et al., 2007). Motive force may decrease
with age as arteriosclerosis results in stiffening vessels, reducing ISF clearance, which could
exacerbate Aβ deposition (Bakker et al., 2016).
Another pathway for Aβ clearance was recently defined by Maiken Nedergaard’s group,
termed the glymphatic pathway (Iliff et al., 2012). This pathway is characterized by the influx of
CSF along arteries into the ISF, which then drains along large caliber paravenous spaces (e.g.
internal cerebral and caudal rhinal veins). The glymphatic pathway is heavily dependent on the
expression of aquaporin4 (AQP4), a water-selective channel on astrocytic end-feet responsible
for regulating water homeostasis. These channels facilitate fluid movement in the interstitium,
creating a current that drives ISF clearance. By imaging the movements of fluorescent-tagged Aβ
injected into the brain parenchyma, researchers found that Aqp4 deletion reduced Aβ clearance
by over 50% (Iliff et al., 2012). Another important factor affecting the rate of clearance is sleep.
During sleep, the volume of the interstitial space increases, resulting in increased convective
flow and enhanced Aβ clearance (Xie et al., 2013). This volume change is proposed to occur due
to changes in astrocyte cell volume.
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Proteolytic Aβ Degradation
Aβ in the ISF is the target of peptidases that reside both in the ISF and on cell
membranes. One of the most studied of these is the neutral metalloendopeptidase, neprilysin
(NEP). NEP is a type II membrane protein whose catalytically active domain is exposed to the
extracellular space. Catabolism of Aβ as measured by injected radiolabeled Aβ into the
hippocampus is greatly minimized following treatment with thiorphan, a NEP inhibitor (Iwata et
al., 2001). Additionally, disruption of NEP expression results in increased levels of soluble Aβ as
well as increased Aβ deposition. In line with these findings, AD brains exhibit lower levels of
NEP, particularly in regions vulnerable to AD pathology (Baranello et al., 2015).
Another enzyme associated with Aβ degradation is the insulin-degrading enzyme (IDE).
Though IDE is primarily a cytosolic protease, it can reside in the plasma membrane and in the
extracellular space. IDE knock-out in Alzheimer’s mouse models display a significant increase
in Aβ levels as compared to wild-type littermates, where IDE overexpression results in a 50%
reduction in both soluble and insoluble Aβ levels (Tanzi et al., 2004). Like NEP, IDE expression
is increased with age (Baranello et al., 2015).
Beyond NEP and IDE, other enzymes linked to Aβ catabolism include endothelinconverting enzyme (ECE), angiotensin converting enzyme (ACE), and the matrix
metalloproteinases (MMPs). ECE-1 preferentially cleaves Aβ40 over Aβ42, raising the 40:42 ratio
of Aβ production, though not influencing levels of externally introduced Aβ. In vitro studies
demonstrated that ACE has the ability to degrade Aβ, but its inhibition or genetic disruption do
not regulate Aβ levels in vivo. MMP-2 and MMP-9 have both been found to directly cleave Aβ.
MMP-9, in fact, can degrade both soluble and fibrillar Aβ and is found in astrocytes surrounding
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amyloid plaques in AD mouse models, potentially acting to reduce plaque load (Yan et al.,
2006). Furthermore, MMP expression in AD patients is increased and is stimulated by Aβ (Tanzi
et al., 2004).
Cellular Uptake and Degradation
The final pathway for Aβ clearance is its uptake by surrounding neurons and glia and
intracellular degradation. Neurons can take up Aβ from the extracellular space using a number of
potential receptors, including LRP1. As discussed earlier, LRP1 is expressed on the epithelial
cells of the BBB and aids in Aβ transcytosis from the ISF to the blood (Storck et al., 2015). In
addition to this, LRP1 is expressed in the postsynaptic region of cell body of neurons where it
can bind and internalize soluble Aβ (Kanekiyo et al., 2011). Neuron-specific deletion of LRP1
results in slowed ISF Aβ clearance and increased Aβ deposition. Once Aβ is internalized through
endocytosis, the majority is trafficked through early and late endosomes to the lysosomal
pathway where it is degraded through enzymes such as cathepsin B and cathepsin D (Li et al.,
2012). If lysosomal activity is impaired, such is observed in the early stages of AD, Aβ that
would otherwise be degraded can aggregate in the acidic microenvironment of lysosomes,
possibly seeding additional Aβ aggregates (Li et al., 2012).
Similar to neurons, astrocytes can also endocytose and degrade Aβ (Wyss-Coray et al.,
2003). Extracellular Aβ can be taken up by astrocytes through receptor-mediated endocytosis
using such receptors as formyl peptide receptors (FPRs), leucine-rich glioma inactivated protein
3 (LGI3), and LRP1 (Ries and Sastre, 2016). Enhancing astrocytic lysosomal machinery,
including enhanced cathepsin B and cathepsin D activity, accelerates Aβ clearance, lowers
soluble Aβ levels in the ISF, and ameliorates amyloid plaque load (Xiao et al., 2014). LRP-1 is
22

expressed in astrocytes as well as in neurons. Conditional astrocytic knockdown of LRP-1
impaired Aβ clearance and accelerated Aβ pathology without altering production (Liu et al.,
2017). Astrocytic activation, characterized by cellular hypertrophy and an enhanced expression
of glial fibrillary acidic protein (GFAP), is a key pathological feature in AD brains, observable
early in disease progress (Verkhratsky et al., 2010). Within the degenerating brain, activated
astrocytes can be found surrounding plaques, suggesting a relationship between these two
pathologies. Whether or not activation of astrocytes is protective or harmful in the context of AD
is still under debate (De Strooper and Karran, 2016). Upon activation, many of the normal
functions astrocytes provide become impaired. It is possible that the ability of astrocytes to clear
Aβ may be diminished as well. In support of this concept, a study by Kamphuis et al. (2015)
found that prohibiting astrocyte activation lead to increased expression of genes involved in
lysosomal degradation and the inflammatory response induced in AD mouse models. No change
in amyloid pathology was observed. However, these findings directly conflict with another study
showing that blocking astrocyte activation lead to increased plaque load that they propose may
be due to decreased clearance since Aβ production was unchanged (Kraft et al., 2013). It seems
likely that astrocytes play various roles in modifying AD pathology, and that their overall
function in regard to AD changes throughout disease progression.
Microglia are the final cell type to actively take up and degrade Aβ. Microglia act on
soluble or fibrillar forms of Aβ through both fluid-phase pinocytosis and by phagocytosis, and
activation of microglia with lipopolysaccharide (LPS) leads to a robust increase in Aβ clearance
(Herber et al., 2007). As with astrocytes, there is continued debate over the role of microglia in
AD as well as the broader role of inflammation (De Strooper and Karran, 2016). For example,
the complement system, which initiates the inflammatory response, has both been found to
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increase Aβ load in Alzheimer’s mice or to have no effect on Aβ accumulation (Wyss-Coray,
2006). One pro-inflammatory cytokines, TNF-α, enhances Aβ deposition (Wang et al., 2015).
However, a similar cytokine, IL-6, has an opposing effect. Overexpression of IL-6 results in
extensive gliosis and microglial activation, boosting levels of Aβ phagocytosis and decreased
plaque burden (Chakrabarty et al., 2010). In the past few years, the microglial transmembrane
protein TREM2 has garnered a great deal of attention in the AD following the discovery that
loss-of-function TREM2 mutations increase the risk of LOAD by 3- to 5-fold. 5XFAD
Alzheimer’s mouse models with TREM2 deletion show increased Aβ plaques in a gene dosedependent manner as well as reduced microglial activation, arguing for a protective role of
microglia (De Strooper and Karran, 2016). Though the role of microglia throughout AD
progression is still debated, these immune cells clearly possess the ability to phagocytose and
degrade Aβ.

In Vivo Brain Microdialysis
In the experiments detailed in the following pages, the predominant experimental
technique used is in vivo microdialysis, specifically in the mouse hippocampus. Microdialysis is
a very useful technique to monitor the concentration of neurotransmitter and other molecules
under a certain size in the ISF of awake, freely moving animals. Microdialysis was originally
developed in the 1960s and 70s to measure neurotransmitter levels in the brain (for review see
Chefer et al., 2009). This technique relies on the microdialysis probe, which is composed of a
tubular cannula with a semi-permeable tip of dialysis membrane. A solution lacking the analyte
of interest (i.e. Aβ) is constantly perfused through the probe via pump. In my experiments, the
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perfusion buffer is artificial CSF supplemented with bovine serum albumin (BSA) to block the
binding of Aβ to the walls of the tubing and probe. A guide cannula for the probe is surgically
implanted in the brain, and the probe is later carefully inserted into this cannula and into the
brain. Once inserted, the dialysis membrane allows for the free diffusion of molecules of and
under a specific molecular weight in and out of the perfusion buffer. In the experiments
described here, Aβ monomers in the ISF are able to move down their concentration gradient
from the ISF into the perfusion buffer, while compounds added to the perfusion buffer (e.g.
AMPA) flow from the probe into the ISF simultaneously. The perfusate then moves past the
dialysis membrane into the outflow tubing where it is collected and analyzed for Aβ
concentration. The percentage of analyte that is collected in the perfusate, the relative recovery
rate, is affected by a number of factors such as the surface area of the probe membrane,
membrane material, diffusional characteristics of the analyte, flow rate of the perfusion buffer,
hydrophobicity of the analyte, and analyte molecular weight (Shippenberg and Thompson,
2001). The molecular weight cut-off (MWCO) of the probe refers to the highest molecular
weight an analyte can be at which 90% is retained by the membrane. A higher MWCO means
that a probe can reliably collect larger analytes. For my thesis work, I used a microdialysis probe
with a MWCO of 32kDa, meaning that the 4kDa Aβ peptide can easily diffuse across the
membrane. Recovery is proportional to flow rate, such that a slower flow rate results in greater
recovery. A faster flow rate, however, results in greater collected perfusate volume, which may
be necessary for analyte analysis. The choice of flow rate, then, is a compromise between a
greater rate of recovery and temporal resolution.
Recovery of ISF Aβ via microdialysis was pioneered by Cirrito et al. in 2003. The
authors used in vitro experiments to characterize the recovery of Aβ by microdialysis in a
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controlled environment. The percentage recovery coefficient of the probe was calculated using
the interpolated zero flux method. In this method, a range of flow rates were used and the
concentration of Aβ collected at each were collected. These data were plotted to construct a
recovery curve from which the theoretical recovery from a zero flow rate can be extrapolated.
The mean percentage recovery of recoverable, soluble Aβ in the solution was approximately
10%. Furthermore, the study showed that they were able to collect and measure Aβ40 and Aβ42,
as well as both transgenic and murine Aβ (Cirrito et al., 2003).
Aβ measurement using microdialysis has a number of advantages over other sampling
techniques. Primarily, microdialysis allows us to monitor changes in Aβ levels dynamically, ever
hour, in response to treatment within the context of an intact brain. As discussed in this
introduction, the regulation of Aβ levels in the ISF is incredibly complex and involves neurons,
glia, and the circulatory system working together, something that cannot be properly
recapitulated in vitro. The main technique used to quantify changes in Aβ levels in animal
models is done in brain lysates. Besides the loss of temporal resolution, tissue lysis captures all
pools of Aβ, and the ISF pool of Aβ most faithfully reflects local production and clearance
(Cirrito et al., 2003). In addition to these advantages, microdialysis always us to use reverse
microdialysis to directly perfuse drugs and other compounds through the probe and into the
hippocampus, bypassing the troublesome blood brain barrier.
Microdialysis does come with its disadvantages, however. The temporal resolution is
limited by recovery efficiency and the amount of sample needed for analyte analysis. To measure
Aβ40 levels in an Alzheimer’s mouse model, this requires sampling every hour. However, to
measure analytes of lower concentrations such as Aβ42 or murine Aβ, even more temporal
resolution must be given up in favor of a larger sample volume. Microdialysis is an invasive
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technique and tissue damage is unavoidable. Furthermore, we have observed a significant level
of gliosis surrounding the probe after a few days of sampling. The size of the microdialysis probe
is such that the technique is limited to areas sufficiently capacious to surround the probe. The
murine hippocampus is large enough to accommodate a probe, but any regional differences
within the structure are undetectable. When using reverse microdialysis, the delivery efficiency
of the drug or compound is difficult to measure, as is its rate of diffusion through the target
tissue. Thus, the drug concentrations stated are always the starting concentrations and not the
actual concentration delivered. Despite these drawbacks, microdialysis remains a useful tool to
identify factors that regulate ISF Aβ levels in awake mice over a period of days.

Alzheimer’s Disease Mouse Models
Murine Aβ exists in the rodent brain in picomolar range (human Aβ in AD brains is in the
nanomolar range) and, due to only three substitutions, does not aggregate into amyloid
formations (Price et al., 1995; Cirrito et al., 2003; Esquerda-Canals et al., 2017). The discovery
of EO-FAD genes, therefore, was pivotal to developing an animal model for AD. The first
transgenic mouse model that developed AD-type neuropathology overexpressed human mutant
V717F APP and exhibited neuritic plaques, synaptic loss, astrocytosis, and microgliosis (Games
et al., 1995). Since then, approximately 80 mouse models using EO-FAD genes have been
generated utilizing various combinations of mutations in human APP, PSEN1, and PSEN2
(www.alzforum.org/research-models). Mice that overexpress human mutant APP, like the
Games et al. model, develop diffuse and dense amyloid plaques within around 6-12 months of
age, depending on the level of overexpression and the mutation used. The most commonly used
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APP mutations include the K670N/M671L (Swedish), V717F (Indiana), E693G (Artic), E693K
(Dutch), and V717I (London) mutations(Kitazawa et al., 2012). The most used of these is the
Swedish double mutation, which increases overall APP expression by increasing β-secretase
cleavage of APP (Haass et al., 1995). Presenilin transgenic mice do not develop plaque
pathology, although the ratio of Aβ42/Aβ40 is increased. Therefore APP and PSEN mutations are
often combined, leading to mice that form plaques at earlier ages than single APP transgenic
mice.
We chose to use a double transgenic mouse in the following experiments, specifically the
APPswe/PSEN1dE9 mouse model (also known as APP/PS1 or Borchelt mice). These mice were
developed by co-injecting two vectors encoding a chimeric mouse/human APP harboring the
Swedish mutation and a human PSEN1 with a ΔE9 mutation (Jankowsky et al., 2001). These
mice begin developing Aβ deposits around the age of six months and exhibit hippocampal and
cortical plaques by nine months (Jankowsky et al., 2004). Gliosis, LTP impairment, dysfunctions
in learning and memory, and limited neuronal loss are also observed (Li et al., 2015). The mice
used in these studies are hemizygous on the congenic C57Bl/6J background. Because we sought
to investigate factors that influence AD pathogenesis that, by definition, occur prior to plaque
development, the mice used in these experiments were two to four months of age. By using
young mice, we were able to examine levels of soluble Aβ without having to account for the
amyloid sink that occurs around plaques or for Aβ escaping plaques. These mice do not develop
any tau pathology.
Of course, these mouse models are unable to completely recapitulate the full pathology
and symptomology seen in true AD. For example, the appearance of plaques and exhibition of
cognitive deficits seen in the models do not follow the same temporal pattern seen in human AD.
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Importantly, these mice fail to exhibit neurodegeneration. Mice made utilizing EO-FAD
mutations alone do not develop neurofibrillary tangles. In some mice, phosphorylated tau does
occur, but no paired helical filaments of tau are observed. Mice with tau mutations have been
made and crossed with EO-FAD mutations, resulting in mice that exhibit both plaques and
tangles. While these models show both fundamental AD pathologies, they still represent a
composite of two distinct diseases and do not follow the same temporal and spatial properties in
the human disease (Oddo et al., 2003; Elder et al., 2010). Though mouse models of AD clearly
fail to faithfully represent human AD, these models are still invaluable tools for understanding
particular aspects of the disease and have helped us gain a greater understanding of AD
pathogenesis and pathology.

Summary
Alzheimer’s disease (AD) is a pressing issue, affecting one in ten people aged 65 and
older. While most other major causes of death have decreased in prevalence, AD has experienced
an 89% increase in deaths (www.alz.org/facts). Increasing research and failed clinical trials
demonstrate that early prevention of AD, starting years before symptoms emerge, might be the
most effective way to combat this devastating disease. Understanding how AD develops and the
factors that contribute to its pathological origins will be vital to develop preventative
therapeutics. Though Aβ does not drive many of the symptoms and pathology displayed in AD
progression, its toxic aggregation clearly plays an important role in pathogenesis. The regulation
of extracellular Aβ levels, which determine the probability of aggregation, is complex and
involves both pre- and postsynaptic neuronal signaling. The work described in this document
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explores the regulation of Aβ by NMDA and AMPA receptors, the glutamate receptors
responsible for mediating synaptic plasticity. We aim to describe how these two prominent and
abundant glutamate receptors affect AD pathogenesis so that we may identify new therapeutic
strategies.
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Chapter 2
NMDA Receptor Regulation of Amyloid-β Levels through
Extracellular Signal-Regulated Kinase

31

ABSTRACT
The extracellular concentration of soluble, monomeric Aβ is a critical factor for the initiation and
rate of aggregation into toxic species, such as oligomers, fibrils, and plaques. Factors that
influence Aβ production, therefore, have the potential to modulate disease progression. Research
from our lab has shown that high levels of NMDA-R activation result in a significant decrease in
Aβ levels dependent on the activation of the MAP kinase/extracellular signal-regulated kinase
(ERK) signaling cascade by calcium influx through the NMDA-R. Evidence suggests that
activated ERK decreases Aβ production by altering APP processing. Certain other receptors that
activate ERK do not show this decrease in Aβ production, suggesting that NMDA-Rs act on
ERK and Aβ through a selective pathway. Defining this pathway may undercover molecules that
can selectively decrease Aβ in a way that global NMDA-R or ERK activation cannot. By
selectively antagonizing the NMDA-R subunits GluN2A and GluN2B during NMDA treatment,
I found that neither subunit is responsible for the effect of NMDA-Rs on Aβ levels. Using virally
driven RNA interference to knockdown expression of the two ERK isoforms, ERK1 and ERK2, I
determined that ERK signaling to regulate APP processing is not isoform-specific. Furthermore,
I found that NMDA-Rs do not act on ERK and Aβ production through calcium/calmodulindependent protein kinase II (CaMKII), protein kinase A (PKA), or protein kinase C (PKC)
signaling.

INTRODUCTION
The N-methyl-D-aspartate (NMDA) receptor is an ionotropic glutamate receptor
activated by the concurrent binding of glutamate and postsynaptic depolarization, with either
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glycine or D-serine acting as coagonist. NMDA-Rs are nonselective cation channels, allowing
the flow of sodium (Na+) and calcium (Ca2+) into the cell and potassium (K+) out. These
heterotetrameric receptors are composed of two GluN1 subunits and two GluN2A-D subunits.
Which GluN2 subunits make up the receptor help determine its electrophysiological and
pharmacological properties (Hunt and Castillo, 2012).
NMDA-R’s permeability to Ca2+ and its coincidence-dependent activation make these
receptors critical to synaptic plasticity and memory formation. Calcium is highly buffered within
the cytoplasm so that even very small changes in Ca2+ concentration can have dramatic effects.
Depending on the level of Ca2+ influx induced by NMDA-R activation, Ca2+ signaling can lead to
either synaptic plasticity and cell survival pathways or excitotoxicity and cell death pathways.
These opposing roles of NMDA-Rs are thought to be mediated by the cellular localization of the
channels; synaptic NMDA-Rs are associated with neurotrophic effects while extrasynaptic
NMDA-Rs seem to activate pro-death pathways (Hardingham et al., 2002; Hardingham and
Bading, 2010). The concept that only extrasynaptic receptors are responsible for NMDA-Rmediated excitotoxicity is not without contention. Wroge et al., for example, found that synaptic
NMDA-Rs are toxic in response to certain endogenous and exogenous insults, indicating that
NMDA-R functions are more complex than proposed by the extrasynaptic NMDA-R hypothesis
(Wroge et al., 2012).
Another possible explanation for the dichotomous roles of NMDA-Rs might lie in their
subunit composition. Synaptic sites seem to be primarily composed of GluN2A-containing
NMDA-Rs, which preferentially bind with postsynaptic density protein-95 (PSD-95). On the
other hand, extrasynaptic sites are enriched with GluN2B-NMDA-Rs, which interact with
synapse-associated protein-102 (SAP-102) (Papouin et al., 2012; Papouin and Oliet, 2017). This
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distinction is not perfect, however, and GluN2A and GluN2B can be found at both cellular
locations (Wang et al., 2016). The subunit composition of NMDA-Rs does appear to affect their
signaling pathways. Importantly, presence of either GluN2A or GluN2B determines the direction
by which the NMDA-R regulates ERK activity, though there are conflicting studies on this issue.
Multiple groups have found that GluN2A-containing receptors signal to activate ERK while
GluN2B-containing receptors inhibit ERK (Hardingham, 2006; Ivanov et al., 2006a; Li et al.,
2006; Wang et al., 2015). Other studies, however, link GluN2B-containing receptors to ERK
activation (Krapivinsky et al., 2003).
Given that NMDA-Rs are implicated in both memory formation and cell death, it is not
surprising that these receptors have been linked with AD pathophysiology. Numerous studies
have shown that certain forms of Aβ have toxic effects on synapses (for review see Malinow,
2012; Zhang et al., 2016). Overproduction of Aβ results in depressed glutamatergic signaling in
hippocampal CA1 pyramidal neurons both through reduced receptor transmission as measured
by electrophysiology and decreased dendritic spine density (Kamenetz et al., 2003; Shrestha et
al., 2006). Amyloid-β appears to enhance long-term depression (LTD)-like synaptic weakening,
acting through common signaling molecules such as calcineurin and caspase-3, while
simultaneously diminishing long-term potentiation (LTP; Kamenetz et al., 2003; Malinow,
2012). Interestingly, Aβ-mediated impairments in LTP can be blocked using NMDA-R
antagonists, directly linking Aβ toxicity to NMDA-Rs. Brains from AD animal models express
lower levels of glutamate transporters, which would result in decreased glutamate uptake and
more glutamate in the synapse (Zhang et al., 2016). In support of this concept, Aβ decreases
glutamate uptake by cultured astrocytes (Matos et al., 2008). Lastly, memantine, a low-affinity
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NMDA-R antagonist, has been approved by the FDA for treatment of AD patients and appears to
mitigate some aspects of cognitive loss in certain patients.
Knowing that NMDA-Rs are implicated in later stage AD pathology, our lab and others
asked if they might also be involved in AD pathogenesis, specifically in Aβ production. As
discussed in the introduction to this document, conflicting studies conducted in vitro reported
that NMDA-R activation either increased Aβ production through increased BACE activity
(Lesné et al., 2005) or decreased Aβ levels by boosting α-secretase activity (Hoey et al., 2009).
Using microdialysis in an AD mouse model, our lab found that NMDA-Rs actually have
opposing effects on Aβ levels depending on the level of receptor activation and the amount of
Ca2+ conducted through the channel (Verges et al., 2011). Lower levels of NMDA increased Aβ
levels by increasing synaptic activity-dependent APP processing. This effect was blocked by
inhibiting action potentials with tetrodotoxin (TTX). Conversely, high NMDA levels reduced the
amount of Aβ produced, despite the presence of TTX. This effect was shown to require
activation of extracellular signal-regulated kinase (ERK), which signals through an undefined
pathway to increase α-secretase APP processing (Verges et al., 2011). Defining the steps from
NMDA-R activation and ERK signaling is one of the questions addressed in this chapter.
The ERKs (ERK1, ERK2, ERK3/4, ERK5, and ERK7) are part of a family of mitogenactivated protein kinases (MAPKs) that are activated by a variety of signals and mediate myriad
cellular processes. ERK1/2 are the most common isoforms expressed in the CNS and express
84% sequence homology. ERK2 is expressed relatively more than ERK1, though the expression
ratio is region-specific. In the hippocampus, the ratio of ERK1 to ERK2 levels is 0.33 (Ottiz et
al., 1995). Both isoforms are expressed throughout the brain and both are primarily neuronal
(Samuels et al., 2009). Traditionally thought to have identical roles, the recent ability to
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genetically inhibit individual ERK isoforms has revealed distinct functions for ERK1 and ERK2
(Yu, 2012). For example, ERK1 has been implicated in protection against NMDA-induced
neuronal distress (Nakazawa et al., 2008) while ERK2 is involved in AMPA-R-mediated cell
death (Yu et al., 2010).
Once ERK is phosphorylated and activated by MAP kinase kinase (MEK), it
phosphorylates its many cellular targets or translocates into the nucleus to regulate gene
expression (Samuels et al., 2009). There are over 160 substrates for ERK already identified that
regulate a huge variety of cellular tasks, sometimes even mediating opposing processes (Yoon
and Seger, 2006). In order to maintain signaling specificity, the timing of ERK activation as well
as its subcellular localization must be highly regulated (Pouysségur et al., 2002).
ERK signaling has been strongly implicated in synaptic plasticity related to learning and
memory, particularly the induction of LTP (English and Sweatt, 1996). As part of these studies, a
number of signaling molecules that activate ERK in the context of LTP have been identified.
Bading and Greenberg (1991) established that NMDA-R signaling leads to ERK activation, and
subsequent studies have found that this pathway involves multiple possible signaling molecules
(Bading and Greenberg, 1991). Which of these possible signaling pathways are responsible for
linking NMDA-Rs to Aβ production remains unknown. By reviewing the literature, we have
identified the four most likely candidates that link NMDA-R activation to ERK in our system: 1)
calcium/calmodulin-dependent protein kinase II (CaMKII; (Chen et al., 1998; Zhu et al., 2002a)
2) protein kinase C (PKC; Kurino et al., 2002; Gangarossa and Valjent, 2012) 3) protein kinase
A (PKA; English and Sweatt, 1996) and 4) Ras-specific guanine nucleotide-releasing factor
(RasGRF), a guanine-nucleotide exchange factor for Ras (Krapivinsky et al., 2003; Feig, 2011).
Calcium influx through NMDA-Rs causes activation of CaMKII, PKC, and PKA-dependent
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signaling pathways that can activate the ERK signaling cascade. In contrast, RasGRF is normally
bound to NMDA-Rs; upon calcium influx it dissociates from the receptor and directly activates
ERK signaling.
In this study, we sought to determine the pathway through which NMDA-Rs act to
decrease Aβ production by investigating the signaling molecules linking NMDA-Rs to ERK
activation, by identifying the subunit composition of NMDA-Rs that initiate this response, and
by distinguishing the differential roles of ERK1 and ERK2 isoforms in NMDA-R-dependent Aβ
production. The ultimate goal of these experiments was to identify specific molecular players
key to decreasing Aβ production caused by glutamatergic signaling.

MATERIALS AND METHODS
Animals
The mice used for these studies were hemizygous APPswe/PS1ΔE9 (APP/PS1; Jankowsky et al.,
2001, 2004) and bred on a wild-type C3H/B6 background or littermate controls (WT). Original
transgenic breeders were purchased from Jackson Laboratory (Bar Harbor, Maine), and colonies
were maintained at Washington University. Equal numbers of male and female mice were used
in each study at 2-4 months of age. All studies were performed in accordance with the guidelines
of AAALAC and the Institutional Animal Care and Use Committee (IACUC) at Washington
University.
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Aβ Microdialysis
In vivo microdialysis was performed in awake and behaving APP/PS1 mice as previously
described (Cirrito et al., 2003, 2011). Briefly, guide cannulas (BR-style, Bioanalytical Systems,
West Lafayette, IN) were stereotaxically implanted above the left hippocampus, coordinates
bregma -3.1mm, 2.5mm lateral to midline, and 1.2mm below dura at a 12° angle. The cannulas
were securely affixed to the head with dental cement, and microdialysis probes (BR-2, 2mm,
38kDa MWCO, Bioanalytical Systems) were inserted into the hippocampus through the guide
cannula. In APP/PS1 mice, probes were perfused with artificial cerebrospinal fluid (aCSF;
1.3mM CaCl2, 1.2mM MgSO4, 3mM KCl, 04mM KH2PO4, 25mM NaHCO3, and 122mM NaCl,
pH 7.35) with 0.15% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO) at a rate of
1.0µL/min with samples of hippocampal ISF collected every 90 minutes during basal collection
or every hour during treatment. Basal sampling began at least 16 hours following surgery. These
experiments took place under constant light conditions to diminish circadian-related fluctuation
in Aβ levels. At the conclusion of the experiment, all ISF samples were analyzed for Aβx-40 levels
by sandwich ELISA.

Compounds
Reverse microdialysis was used to administer compounds directly into the hippocampus. Drugs
were diluted into the perfusion buffer of artificial CSF and 0.15% BSA, allowing the drugs to
diffuse into the brain continuously for the duration of the experiment at the same time that Aβ is
collected. Due to the complexity of determining the final concentration of compound delivered to
the brain, only the starting concentrations of drugs in the perfusion buffer are given. We estimate
approximately 10% of the drug is delivered across the probe membrane where it is further
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diluted in the brain CSF. NMDA (40µM), MK801 (100µM), and ifenprodil (50µM) were
purchased from Sigma. KT5720 (800nM), KN-93 (50µM), Go6983 (1µM), Ro25-6981 (5µM),
and TCN201 (100µM) were purchased from Tocris Bioscience (Ellisville, MO).

Aβ Sandwich ELISAs
ISF samples were analyzed for Aβx-40 or Aβx-42 concentration using methods previously
described (Fisher et al., 2016). A mouse monoclonal anti-Aβ40 capture antibody (mHJ2) or antiAβ42 capture antibody (mHJ7.4) made in-house was used in conjunction with a biotinylated
central domain detection antibody (mHJ5.1) and streptavidin-poly-HRP-40 (Fitzgerald
Industries, Acton, MA). Super Slow ELISA TMB (Sigma) was then used to develop, and
absorbance was read by a BioTek Epoch plate reader at 650 nm. The same assay can be used for
both human and murine Aβx-40. Standard curves for ELISAs were generated using synthetic
human Aβ40 or Aβ42 (American Peptide, Sunnyvale, CA). Basal levels of ISF Aβ levels were
calculated by averaging the Aβ concentrations taken every 90 minutes for 9 hours prior to drug
treatment. All Aβ levels for each mouse were then normalized by calculating percent of basal for
each point. Mean ± SEM per group are shown.

AAV Vector Production
The packaging cell line, HEK293, was maintained in Dulbecco’s modified Eagles medium
(DMEM), supplemented with 5% fetal bovine serum (FBS), 100 units/ml penicillin, 100mg/ml
streptomycin in 37°C incubator with 5% CO2. The cells were plated at 30-40% confluence in
CellSTACS (Corning, Tewksbury, MA) 24 h before transfection (70-80% confluence when
transfection). 730mg pAAV2/8, 1180 mg pHelper, and 590mg rAAV transfer plasmid
39

containing the gene of interest were co-transfected into HEK293 cells using the calcium
phosphate precipitation procedure (Zolotukhin et al., 2002). The cells were incubated at 37°C
for 3 days before harvesting. The cells were lysed by three freeze/thaw cycles. The cell lysate
was treated with 25 U/ml of Benzonaze at 37ºC for 30 min followed by iodixanol gradient
centrifugation. The iodixanol gradient fraction was further purified by column chromatography.
HiTrap Q column (GE Healthcare) was used for AAV8. The eluate was concentrated with
Vivaspin 20 100K concentrator (Sartorius Stedim, Bohemia, NY). Vector titer was determined
by Dot blot assay.

Viral Injections and tissue lysis
APP/PS1 mice aged 2-4 months old were stereotaxically injected unilaterally into anterior and
posterior sites of hippocampus with shERK1, shERK2, or shScrambled. Injection coordinates for
the anterior site were -1.65mm anterior/posterior, -1.2mm medial/lateral, and -1.75mm
dorsal/ventral. Injection coordinates for the posterior site were -2.9mm anterior/posterior, 2.7mm medial/lateral, and -2.2mm dorsal/ventral. Virus was injected at a rate of 0.5µL/min with
2µL/injection site. After two weeks to allow for viral integration and gene knockdown, mice
were sacrificed and perfused with 4% paraformaldehyde, followed by brain dissection and snapfreezing of the hippocampus on dry ice. Tissue was homogenized by sonication at a 10:1
volume:wet weight in 150mM NaCl, 50mM Tris, pH 7.4, 0.5% deoxycholic acid, 0.1% SDS, 1%
Triton X-100, 2.5mM EDTA, and protease inhibitors.
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Western blotting
SDS PAGE and Western blotting was used to determine the amount of ERK1 and ERK2
knockdown in the hippocampus. Gel electrophoresis of 20µg protein samples was performed
under reducing conditions using 4-12% Bis-Tris NuPAGE gels (ThermoFisher Scientific,
Waltham, MA) and then transferred to nitrocellulose membrane. Blots were probed for p44/p42
MAPK (aka ERK; 1:1000; Cell Signaling Technology, Danvers, MA) and tubulin (1:2500;
Sigma). HRP-conjugated donkey anti-rabbit IgG (1:250; Cell Signaling Technology, Danvers,
MA) and HRP-conjugated Amersham ECL sheep anti-mouse IgG (1:500; GE Healthcare,
Chicago, IL) were used as secondary antibodies. Membranes were developed using SuperSignal
West Pico Substrate (ThermoFisher) and imaged using the Kodak ImageStation 440CF
(Rochester, NY). Band intensity was quantified using the Kodak 1D Image Analysis software,
and normalized using tubulin signals as loading controls. Values shown are these normalized
band intensities relative to the experimental control group. Mean ± SEM per group are shown.

Statistical Analysis
Data in figures are presented as mean ± SEM. Prism 6.0b for Mac OS X (GraphPad, San Diego,
CA) was used for all statistical analyses. Two-tailed unpaired t-tests were used to compare
between two groups. One-way or two-way ANOVA was used when comparing one or two
independent variables, respectively, between multiple groups. Analysis of microdialysis
experiments was performed by averaging the final three data points of a specific treatment period
and using one-way or two-way ANOVA with Dunnett’s correction for multiple comparisons.
Values were accepted as significant is p≤0.05.
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RESULTS
Receptor subunit composition is not a factor in NMDA-R Aβ regulation
Despite highly similar amino acid sequences, the GluN2A and GluN2B NMDA-R
subunits often exhibit distinct binding partners, pharmacological properties, and cellular roles
(Zhang and Luo, 2013). A number of highly selective subunit-specific antagonists have been
developed to differentiate the effects of GluN2A versus GluN2B due to the hypothesis that
subunit composition determines receptor signaling for either neuronal survival or death
(Hardingham, 2006). Which subunit is responsible for ERK activation is a well-studied question,
but a consensus is yet to be reached (Krapivinsky et al., 2003; Ivanov et al., 2006b; Li et al.,
2006). In order to determine if NMDA-Rs activate ERK and decrease Aβ production through
subunit-specific signaling, we administered subunit-specific antagonists to an Alzheimer’s
mouse model using hippocampal microdialysis (Fig. 2.1 A,B). In order to assess soluble ISF Aβ
levels before plaque formation, we used young, 2 to 4 month-old APPswe//PS1Δe9 hemizygous
(APP/PS1) mice (Jankowsky et al., 2001, 2004).
Subunit-specific antagonists were administered directly into the hippocampus using
reverse microdialysis for 6 hours following collection of basal ISF samples. NMDA (40µM
starting concentration) was then added for an additional 18 hours. Two different, highly selective
GluN2B antagonists were used: Ro25-6981 (>1000-fold specificity over GluN2A) and ifenprodil
(>400-fold specificity over GluN2A). Neither antagonist prevented the decrease in Aβ levels
seen with NMDA treatment (Fig. 2.1 A,B). Development of a GluN2A-specific antagonist has
not yielded as much success as with GluN2B antagonists. Recent studies, however, have
identified a potent GluN2A antagonist, TCN201, which noncompetitively blocks GluN2A42

containing receptors in a manner dependent on the GluN1-agonist concentration (Edman et al.,
2012). As seen with the GluN2B antagonists, blocking GluN2A signaling did not influence the
effect of NMDA treatment on ISF Aβ levels. Importantly, NMDA failed to decrease Aβ levels
when all NMDA-Rs were blocked with MK801, a noncompetitive NMDA-R antagonist.
Together, these results argue that neither GluN2A-containing nor GluN2B-containing receptors
alone are responsible for NMDA-Rs’ effect on Aβ. Instead, it is likely that both populations of
receptors redundantly signal to regulate Aβ production. It is important to note, however, that
these subunit-specific antagonists do not completely inhibit NMDA-R currents. Additionally, the
selectivity of TCN201 for GluN2A subunits depends on the GluN1 agonist concentration.

ERK1 or ERK2 is sufficient for NMDA-R-mediated Aβ regulation
The two prominent isoforms of ERK, ERK1 and ERK2, display both overlapping and
distinct roles in cellular signaling. Until the development of targeted genetic inactivation of
either gene, these ERK isoforms have been considered functionally identical due to their close
homology. Isoform-specific ERK knockout and knockdown studies, however, demonstrated that
ERK1 and ERK2 have distinct characteristics. Pharmacological tools frequently used to
manipulate ERK activity, such as the inhibitors U0126 and FR180204, act equally on all ERKs
and therefore fail to distinguish specific ERK isoform roles.
In order to determine if NMDA-R-ERK signaling acts on Aβ in an isoform-specific
manner, we stereotaxically injected purified short-hairpin RNA (shRNA) against ERK1 or ERK2
packaged into adeno-associated virus serotype 8 (AAV8) and driven by a U6 promoter to
knockdown expression of ERK1 or ERK2 in the hippocampus of young APP/PS1. Western blot
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analysis showed that AAV-transduction of shRNA against ERK1 (shERK1) resulted in a
decrease by about 45% compared to controls injected with scrambled shRNA (shScrambled),
while ERK2 expression decreased by approximately 42% (shERK2; Fig. 2.2A). Microdialysis
probes were then implanted into the hippocampus of these shERK1 and shERK2 mice and 40µM
NMDA was infused into the brain via reverse microdialysis. If NMDA-Rs acted on Aβ through a
specific ERK isoform, we would expect that decreased expression of this isoform would
attenuate the decrease in Aβ seen following NMDA treatment. However, NMDA treatment led
to indistinguishable decreases in ISF Aβ levels in all groups, regardless of ERK1 or ERK2
knockdown (Fig. 2.2B). These results indicate that NMDA-Rs do not signal to regulate Aβ
through a specific ERK isoform and that either ERK1 or ERK2 is sufficient to see effects on Aβ
following NMDA treatment. Our RNAi approach, however, only decreased expression of each
ERK isoform and did not abolish EKR1 or ERK2 activity entirely. It is possible that the
remaining ERK expression allowed sufficient signaling to mediate NMDA-R signaling,
obscuring our results.

NMDA-R-ERK signaling to Aβ does not require PKA, CaMKII, or PKC
ERK phosphorylates an array of cellular targets and regulates a large variety of signaling
cascades and cellular roles. Despite its multifarious functions, ERK mediates very distinct,
selective pathways. Precise and exquisite regulation of ERK activation is achieved through
controlled intensity, duration, and subcellular localization of signaling (Pouysségur et al., 2002).
This means that the decrease in Aβ levels observed in our experiments is likely mediated by a
very specific pathway from NMDA-Rs to ERK phosphorylation. By identifying the signaling
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molecules necessary to connect NMDA-Rs to ERK to Aβ, we can define select targets that could
be used to modify Aβ levels.
NMDA-Rs have been observed to signal to ERK through a variety of pathways. Studies
of glutamatergic regulation of synaptic plasticity were the first to link calcium influx through
NMDA-Rs to ERK activation (Bading and Greenberg, 1991; Xia et al., 1996). Chandler et al.
(2000) found that, depending on the level of receptor stimulation, NMDA-Rs exerted
bidirectional control of ERK activation. The stimulatory pathway was dependent on the
activation of calcium/calmodulin-dependent kinase II (CaMKII; Chandler et al., 2000). Further
studies supported these results. For example, NMDA-R signaling was shown to control AMPAR trafficking during synaptic plasticity through CaMKII-dependent activation of ERK (Zhu et
al., 2002a). CaMKII connected to NMDA-Rs through binding to the postsynaptic density 95
(PSD95) complex where it decreased the activity of p135 synaptic Ras-GTPase activating
protein (SynGAP; Chen et al., 1998). Later, synaptic NMDA-Rs specifically were found to
activate ERK through CaMKII (Hardingham, 2006). Additionally, NMDA-Rs were found to
activate ERK through protein kinase A (PKA) activation during LTP in hippocampal slices
(Banko et al., 2004). Protein kinase C (PKC) has also been linked to NMDA-R-dependent ERK
activation (Park et al., 2010).
We utilized pharmacological small-molecule inhibitors of these signaling molecules to
determine if their activity was necessary for NMDA-Rs to signal through ERK to lower Aβ
levels. CaMKII was inhibited with KN-93 (50µM) before and during treatment with 40µM
NMDA via reverse microdialysis in young APP/PS1 mice. Alone, CaMKII inhibition increased
ISF Aβ levels up to 200% over basal levels (Fig. 2.3A,B). At 6 hours of treatment, Aβ levels
appeared to reach a plateau, although it is possible that levels would have increased further with
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longer KN-93 treatment. These results indicate that basal levels of CaMKII activation normally
act to decrease Aβ levels. However, NMDA treatment still decreased Aβ even with CaMKII
inhibition, meaning that CaMKII is not required for the pathway of interest. ISF Aβ levels were
unchanged following inhibition of either PKA (KT5720; 500nM) or PKC (Gö6983; 1µM). As
with CaMKII, neither PKA nor PKC inhibition prevented NMDA treatment from lowering Aβ levels
(Fig. 2.3A,B).
These results argue that NMDA-Rs do not activate ERK and regulate Aβ production through
CaMKII, PKC, or PKA. There are caveats to these experiments, however. While the use of reverse
microdialysis allows us to bypass the BBB, it also prevents us from knowing the specific
concentration of drug that is administered to the hippocampus. We referenced previous in vitro
studies and the published IC50 values for the inhibitors used, but we cannot be sure that the target was
fully inhibited. Treatment with KN-93 increased Aβ levels without NMDA, suggesting that CaMKII
was indeed inhibited. Inhibition of PKA and PKC, however, did not affect Aβ. This could mean that
PKA or PKC signaling is not involved in Aβ regulation, or it could be clue that the targets were not
engaged by their respective inhibitors. These results would be bolstered by secondary measures of
kinase inhibition.

DISCUSSION
Studies carried out in our lab and in others have implicated NMDA-Rs, the receptors
essential for mediating synaptic plasticity, in the regulation of Aβ production; specifically, high levels
of NMDA-R activation initiate an ERK-mediated signaling cascade that increases nonamyloidogenic processing of APP (Lesné et al., 2005; Hoey et al., 2009; Verges et al., 2011). In an
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effort to dissect this pathway, we primarily used microdialysis in APP/PS1 mice to demonstrate that
decreases in Aβ following NMDA treatment is not due to a specific NMDA-R subunit (Fig. 2.1) nor
is it the result of discrete signaling through either ERK1 or ERK2 (Fig. 2.2). Additionally, we have
shown that NMDA-Rs do not activate ERK through CaMKII, PKA, or PKC activation to affect APP
processing (Fig. 2.3).
NMDA-Rs mediate opposing roles in the context of cellular fate. While NMDA-Rs are
responsible for synaptic plasticity, activate pro-survival genes, and protect against oxidative stress,
they are also known to activate pro-death signaling and facilitate excitotoxicity (Hardingham and
Bading, 2010). The mechanistic switch that determines the ultimate direction of NMDA-R signaling
is still under investigation. The degree of NMDA-R activation and the amount of calcium allowed to
enter the cell has been proposed as an explanation for these differential effects (Lipton and Kater,
1989; Chandler et al., 2000; Poo et al., 2000) as have the cellular localization of NMDA-Rs (Sattler
et al., 2000; Ivanov et al., 2006b; Papadia et al., 2008; Hardingham and Bading, 2010) and the
NMDA-R subunit composition (Krapivinsky et al., 2003; Li et al., 2006; Liu et al., 2007). Because
NMDA-R activation can be either protective or toxic through a mechanism that is as yet
undetermined, the use of a NMDA-R agonist to decrease Aβ production is clearly not a feasible
option as an AD therapeutic. Instead, a safer, more selective target must be identified. To this aim, we
sought to address the population of NMDA-Rs responsible for the desired effects on Aβ.
While there is evidence that synaptic NMDA-Rs mediate protective NMDA-R signaling,
selectively targeting synaptic versus extrasynaptic NMDA-Rs is not possible in the complex
environment of a living brain. To achieve greater experimental control over receptor populations, we
turned to an in vitro system. In an in vitro setting, use-dependent antagonists allow for the selective
activation of synaptic or extrasynaptic receptors. However, we were unable to perform these
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experiments after failing to reliably reproduce the effects we observed in vivo following NMDA
treatment in a tissue culture model. Indeed, NMDA treatment did not have consistent effects on
extracellular Aβ levels in the multiple cellular systems we tested: neuro2A cells, a mouse
neuroblastoma cell line expressing APP, SH-SY5Y cells, a human neuroblastoma cell line, and
primary hippocampal neurons from wild-type mice (data not shown). Indeed, the type of medium
used as well as the presence of the supplement B27 appeared to have large effects on Aβ levels
following treatment with NMDA, NMDA-R antagonists, or ERK inhibitors. Thus, we were unable to
specifically target extrasynaptic versus synaptic NMDA-Rs in the context of Aβ production.
The type of GluN2, the main regulatory subunit, present in a NMDA-R shapes the receptor’s
temporal and spatial properties. GluN2A subunits are associated with protective signaling pathways
such as CREB and ERK phosphorylation, while GluN2B-containing receptors are thought to oppose
these survival signals and mediate excitotoxicity (Krapivinsky et al., 2003; Zhang and Luo, 2013).
Furthermore, GluN2A-containing receptors are enriched in synaptic sites and GluN2B-containig
receptors in extrasynaptic locations, though this distinction is not perfect (Petralia et al., 2010;
Petralia and S., 2012). We used subunit-specific antagonists in order to differentiate between GluN2A
and GluN2B signaling and found that antagonizing either subunit was not enough to prohibit NMDA
treatment from decreasing Aβ levels. These results differ somewhat from previous studies that found
that synaptic NMDA-R activation promoted increased α-secretase activity (Hoey et al., 2009) and
that extrasynaptic NMDA-R signaling elevated β-secretase APP processing (Bordji et al., 2010).
Both of these studies targeted NMDA-R subpopulations in vitro and did not examine a subunitspecific effect, however. It could be that the differential effects on Aβ observed by these groups is due
entirely to NMDA-R location and not composition, or that these signaling pathways operate
differently in vitro and in vivo.
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Similar to NMDA-Rs, ERK signaling has a hand in an extensive number of cellular
processes, making it a less than ideal target for therapeutic intervention. ERK has long been
suspected to play a beneficial role in the regulation of Aβ production, but a selective pathway has yet
to be defined (Mills et al., 1997; Goodenough et al., 2000; Manthey et al., 2001; Zhu et al., 2002b).
Specificity could be gained if ERK’s effect on Aβ production is exclusively carried out through one
of the ERK isoforms. Using virally driven RNAi to knockdown either ERK1 or ERK2 in the
hippocampus of APP/PS1 prior to performing microdialysis, we found that neither isoform is
necessary for NMDA-Rs to regulate Aβ production. The use of shRNA against ERK1 or ERK2 was
only able to reduce expression of these isoforms by less than half, however.
In addition to testing isoform-specificity, we searched for the signaling pathway linking
NMDA-Rs to ERK activation. Because ERK cascades are responsible for specific cellular responses,
a high level of regulation must be achieved through precise localization via scaffold proteins and
specific docking sites that allow the binding of certain activators and regulators (Pouysségur et al.,
2002). We tested the top three candidates that have been shown to link NMDA-Rs to ERK
phosphorylation in previous studies: CaMKII, PKA, and PKC. Using inhibitors of these signaling
molecules, we demonstrated that none was necessary for NMDA-Rs to activate ERK and decrease
Aβ production. One possible explanation for this is that there is redundancy in this pathway and
inhibition of no one signal is enough to block the effect. Additionally, due to the constraints of
reverse microdialysis, it is possible that our pharmacological inhibition of these signaling molecules
was incomplete. Future experiments may involve genetic targeting to more reliably silence CaMKII,
PKA, or PKC signaling.
Unlike CaMKII, PKA, or PKC, RasGRF, a Ras-specific GDP/GTP exchange factor and
Ras activator, is directly attached to NMDA-Rs. RasGRF has been found to both activate and
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inhibit ERK signaling depending on the RasGRF isoform activated. Krapivinsky et al. showed
that RasGRF1 bound to the GluN2B subunit, inhibited ERK activity, and promoted LTD
(Krapivinsky et al., 2003). On the other hand, a different group used RasGRF isoform-specific
knockout mice to demonstrate that RasGRF2 associated with NR2A, stimulated ERK, and
promoted LTP (Li et al., 2006; Feig, 2011). Future experiments will need to be done to target
RasGRF and determine if it is necessary for NMDA-R-regulation of Aβ. Because there are no
pharmacological inhibitors developed against RasGRF, a genetic strategy will need to be used.
RasGRF-/- mice have been developed and could be bred with APP/PS1 to determine the effect of
RasGRF on Aβ pathology.

CONCLUSIONS
Amyloid-β production and release into the extracellular space is a pivotal process
contributing to the pathogenesis of AD. Factors that regulate this process are therefore of great
interest as targets for therapeutic intervention. Though NMDA-R signaling and ERK activation
have been shown to decrease production of Aβ, neither NMDA-Rs nor ERK is a viable drug
candidate due to their many cellular roles. We sought to explore this pathway in order to identify
a more selective, viable candidate for pharmacological targeting. Ultimately, we found that
NMDA-R-dependent Aβ regulation is not achieved through specific NMDA-R subunits, through
either ERK isoform, or through CaMKII, PKA, or PKC signaling. Future experiments will
address the roles of synaptic versus extrasynaptic NMDA-Rs as well as RasGRF activation of
ERK.
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Figure 2.1: Subunit-specific antagonism does not affect ISF Aβ levels. A,B) 2-4 month old
APP/PS1 were treated with aCSF (vehicle), Ro25-6981 (5µM; GluN2B antagonist), ifenprodil
(50µM, GluN2B antagonist), TCN 201 (100µM; GluN2A antagonist), or MK801 (100µM;
universal NMDA-R antagonist) for 6 hours, followed by 18 hours of co-treatment of antagonist
with NMDA using microdialysis (n=4-8 mice/group). The last 3 time points of each treatment
were averaged, and the percent change in ISF Aβ levels at the end of NMDA treatment versus
the basal period of sampling was graphed. No antagonist significantly changed ISF Aβ levels on
its own. The addition of NMDA to subunit-specific antagonists (Ro25-6981, ifenprodil, and
TCN 201) decreased ISF Aβ levels by approximately 45%, and there was no difference between
these antagonists. Only treatment with MK801 blocked the effect of NMDA on ISF Aβ.
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Figure 2.2: ERK1 or ERK2 knockdown is insufficient to alter NMDA-R regulation of ISF
Aβ levels. A) ERK isoform knockdown was achieved using AAV delivery of shRNA targeted
against either ERK1 (shERK1) or ERK2 (shERK2) or carrying a nonsense shRNA for control
(shScrambled; n=8 mice/group). Western blot analysis of the hippocampal lysates was used to
quantify the amount of ERK1 or ERK2 protein following knockdown as compared to
shScrambled tissue. The shRNA targeted against ERK1 decreased ERK1 protein levels by
44.87% (p=0.0007) and shRNA against ERK2 decreased its expression by 41.62% (p=0.0029).
B) Young APP/PS1 mice with no viral injection, ERK1 knockdown, or ERK1 knockdown were
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administered NMDA or vehicle (aCSF) for 15 hours via reverse microdialysis. NMDA treatment
decreased ISF Aβ levels by the same amount regardless of isoform knockdown.
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Figure 2.3: Inhibition of PKA, CaMKII, or PKC does not abrogate NMDA’s effects on ISF
Aβ levels.
A,B) Young APP/PS1 mice were pre-treated with either KT5720 (800nM; PKA inhibitor), KN93 (50µM; CaMKII inhibitor), Gö6983 (1µM; PKC inhibitor), or vehicle (aCSF) for 6 hours
before co-treatment with NMDA for 14 hours. The last 3 time points of each treatment were
averaged, and the percent change in ISF Aβ levels at the end of NMDA treatment versus the end
of inhibitor alone treatment was graphed. Though CaMKII inhibition increased ISF Aβ levels on
its own, ultimately NMDA treatment leads to similar decreases in ISF Aβ levels following
CaMKII, PKA, and PKC inhibition.
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Chapter 3
AMPA-ergic Regulation of Amyloid-β Levels in an
Alzheimer’s Disease Mouse Model
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ABSTRACT
Extracellular accumulation and aggregation of the Aβ peptide into toxic multimers is a
key event in Alzheimer's disease pathogenesis. Aβ aggregation is concentration-dependent, with
higher concentrations of Aβ much more likely to form toxic species. The processes that regulate
extracellular levels of Aβ therefore stand to directly affect onset of AD pathology. Studies from
our lab and others have demonstrated that synaptic activity is a critical regulator of Aβ
production through both presynaptic and postsynaptic mechanisms. AMPA receptors (AMPARs), as the most abundant ionotropic glutamate receptors, have the potential to greatly impact Aβ
levels. By performing in vivo microdialysis in APP/PS1 mice, we found that AMPA-R activation
decreases interstitial fluid (ISF) Aβ levels in a dose-dependent manner. Moreover, the effect of
AMPA treatment involves three distinct pathways. Tonic, steady-state activity of AMPA-Rs
normally promotes higher ISF Aβ concentrations. Evoked AMPA-R activity, however, decreases
Aβ levels both by stimulating glutamatergic transmission and activating downstream NMDA
receptor (NMDA-R) signaling or, with longer treatment, by acting independently of NMDA-R
activity. Surprisingly, we found this latter, direct AMPA pathway of Aβ regulation is achieved
through increased Aβ clearance rather than suppressed production. Understanding the pathways
that regulate and maintain Aβ levels prior to AD pathology may provide insights into disease
pathogenesis.

SIGNIFICANCE STATEMENT
Alzheimer’s disease pathology accumulates over many years. Synaptic activity is a strong
regulator of brain Aβ concentration that influences if and when Aβ will aggregate. The
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relationship between synaptic activity and Aβ levels has many facets. Synaptic transmission
drives Aβ secretion into the brain ISF, while neurotransmitter receptor activation regulates Aβ
levels independently of transmission. Here, we show that AMPA-Rs regulate Aβ via several
pathways. AMPA-Rs and NMDA-Rs cooperate to suppress processing of APP into Aβ.
Furthermore, AMPA treatment decreases Aβ levels through enhanced clearance, thus linking
synaptic activity to Aβ clearance for the first time. These data emphasize that Aβ regulation by
synaptic activity involves a number of independent pathways that together determine
extracellular Aβ levels.

INTRODUCTION
Alzheimer’s disease (AD) follows a protracted course with pathology detected years,
even decades before clinical symptoms manifest. The preclinical stage of AD appears to be
initiated by the aggregation of the peptide amyloid-β (Aβ) into toxic oligomers, thereby
triggering a host of biochemical and cellular pathological events (Hardy and Higgins, 1992;
Sperling et al., 2011; Musiek and Holtzman, 2015). The shift from normal production of soluble
Aβ to its pathogenic aggregation is heavily influenced by Aβ’s extracellular concentration.
Consequently, the rate at which Aβ is produced and secreted from the neuron, as well as its
clearance from the extracellular space, is directly linked to the formation of toxic amyloid
species (Meyer-Luehmann et al., 2003; Yan et al., 2009; Bero et al., 2011).
Our lab and others have shown that an important regulator of extracellular Aβ levels is
synaptic activity (Kamenetz et al., 2003; Cirrito et al., 2005b). Elevated synaptic activity drives
clathrin-mediated endocytosis at the presynaptic membrane, thereby increasing endocytosis of
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the amyloid precursor protein (APP) and subsequent Aβ generation (Cirrito et al., 2008). At the
systems level, the regional distribution of amyloid plaque deposition in AD brains correlates with
default mode network connectivity, suggesting that chronic high levels of network activity
contribute to plaque formation (Buckner et al., 2005, 2009). However, not all increased neuronal
activity results in increased Aβ concentrations. Indeed, a number of postsynaptic receptors have
been shown to decrease Aβ production. Stimulation of serotonin receptors activates the
extracellular regulated kinase (ERK) signaling pathway, which enhances α-secretase activity and
non-amyloidogenic APP processing (Cirrito et al., 2011; Fisher et al., 2016). Similarly, M1
muscarinic acetylcholine receptors decrease Aβ levels by enhancing α-secretase activity through
protein kinase C (PKC) activation (Davis et al., 2010; Fisher, 2012). NMDA receptor (NMDAR) activation regulates Aβ levels bidirectionally – low concentrations of NMDA elevate Aβ
levels through increased presynaptic membrane endocytosis, while higher concentrations of
NMDA decrease Aβ production through dendritic, calcium-dependent signaling and increased αsecretase activity (Cirrito et al., 2011). These experiments show that the relationship between
neuronal activity and Aβ production is complex, with even the same receptors in some cases
having opposing effects depending on the extent of activation.
AMPA receptors (AMPA-Rs) are the predominant postsynaptic glutamate-gated ion
channels and are responsible for the majority of fast excitatory transmission in the CNS, making
them well positioned to impact the relationship between Aβ levels and synaptic activity. AMPARs are composed of four subunits (GluA1-GluA4) in a dimers-of-dimers assembly to make up
heteromeric, tetrameric complexes (Chater and Goda, 2014). Within the hippocampus, the
majority of AMPA-Rs are made up of either GluA1 and -2 heteromers, GluA2 and -3
heteromers, or GluA1 homomers (Wenthold et al., 1996). The vast majority of AMPA-Rs in the
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hippocampal pyramidal cells are heteromers containing RNA-edited GluA2 subunits. The
presence of this subunit is highly significant to the biophysical properties of the receptor as it
yields the receptor impermeable to calcium (Sommer et al., 1991). The existence of calciumpermeable GluA1 homomeric receptors remains controversial in the field, as is their possible
physiological role (Lu et al., 2009). Biochemical studies show a small, functional population of
calcium-permeable AMPA-Rs, likely extrasynaptic (Wenthold et al., 1996), while conditional
genetic deletions of each subunit imply that these receptors have no significant effect on AMPAR currents (Lu et al., 2009). This question continues to be pertinent as even a small population of
AMPA-Rs with the ability to initiate intracellular calcium signaling could have an impact on
glutamatergic transmission.
AMPA-Rs are pivotal actors in mediating synaptic plasticity and determining synaptic
strength. In short, a synapse is strengthened with the insertion of AMPA-Rs into the membrane
or weakened when they are endocytosed. AMPA-R trafficking in and out of the postsynaptic
membrane is therefore highly dynamic. Phosphorylation and dephosphorylation of receptor
subunits regulates receptor trafficking through a number of kinases and phosphatases such as
CaMKII, PKA, calcineurin, and PKC (for review see Shepherd and Huganir, 2007). Also
important to determining AMPA-R localization and activity is a troop of AMPA-R-binding
intracellular and extracellular proteins, including proteins with and without PDZ domains (for
review see Braithwaite et al., 2000). An additional route for AMPA-R regulation is receptor
desensitization. AMPA-Rs are rapidly desensitized in a matter of milliseconds following agonist
exposure, leading to short-term depression (Trussell et al., 1993). Dissociation of desensitized
receptors from anchoring proteins results in their fast diffusion out the synaptic membrane and
allows speedy recovery from synaptic depression (Constals et al., 2015).
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In addition to their well-established role as the primary agents of postsynaptic
depolarization, growing evidence suggests AMPA-Rs can act as independent activators of
second messenger signaling (Wang and Durkin, 1995; Wang et al., 1997; Perkinton et al., 1999a;
Hartmann et al., 2004; Rao and Finkbeiner, 2007). AMPA-R activation, for example, has been
found to activate ERK signaling through a pathway that is sensitive to pertussis toxin, suggesting
the participation of G protein (Wang and Durkin, 1995; Hayashi et al., 1999) Within retinal
ganglion cells, AMPA-R activation has the ability to suppress the inward current through the cGMP gated channel, again likely mediated by a G-protein (Kawai and Sterling, 1999).
Furthermore, spontaneous, synaptic glutamatergic transmission maintains dendritic spines
through undefined trophic signals that rely on AMPA-Rs, indicating some signaling initiated by
the receptors (McKinney et al., 1999). These studies and others provide convincing evidence that
AMPA-Rs have the ability to influence the cell through more than just sodium conductance and
depolarization.
The most obvious and fundamental symptoms of AD are deficits in learning and memory.
Studies in both human subjects and mouse models have shown that these deficits are at least in
part mediated by Aβ-induced synaptic changes (Guntupalli et al., 2016b). Increased Aβ levels
caused by overexpression of APP caused increased AMPA-R endocytosis and synaptic
depression in a manner mimicking the natural processes of LTD (Hsieh et al., 2006). Increased
calcium signaling following Aβ treatment decreased PKC-mediated phosphorylation of GluR2
subunits (Liu et al., 2010), and Aβ oligomers induced GluR1 dephosphorylation via calcineurin,
which was associated with spatial memory deficits (Miñano-Molina et al., 2011). GluR3 was
also shown to be important in Aβ-induced AMPA-R dysfunction; treatment with Aβ oligomers
blocked LTP only in GluA3-expressing neurons (Reinders et al., 2016). APP knock-in AD
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mouse models display downscaling of AMPA-R currents with age as well as deficits in LTP and
LTD (Chang et al., 2006). Because deficits in AMPA-R function is clearly linked to AD
pathology, positive AMPA-R modulators (AMPAkines) are being considered as AD therapeutics
that could strengthen excitatory transmission and synaptic plasticity (Swanson, 2009). In aged
rats, AMPAkine treatment rescued dendritic loss and memory deficits associated with aging
(Lauterborn et al., 2016).
Most of the research involving AMPA-Rs and AD has focused on the deleterious effect
of pathological amyloid species on AMPA-Rs (Chang et al., 2006; Hsieh et al., 2006; Shepherd
and Huganir, 2007), while the inverse relationship, that of AMPA-R’s effects on Aβ, has
received much less attention. A notable exception is a compelling study by Hoey et al. (2013),
which reported increased non-amyloidogenic processing of APP following AMPA treatment in
vitro. Given the AMPA-R’s dominant role in synaptic transmission and its active signaling
capabilities, we hypothesized that AMPA-Rs regulate Aβ metabolism.
Using in vivo microdialysis, we found that baseline AMPA-R activity maintains higher
levels of Aβ, whereas evoked activation of AMPA-Rs leads to reduced Aβ levels in the
interstitial fluid (ISF) of the mouse hippocampus. Interestingly, the effect of exogenous AMPA
treatment resolves into two phases. Initially, AMPA-Rs decrease Aβ levels through synaptic
release of glutamate and downstream activation of NMDA-Rs. After prolonged treatment with
AMPA, however, Aβ levels are reduced through an NMDA-R-independent pathway that does
not rely on presynaptic transmission. Surprisingly, we found that AMPA-Rs directly influence
Aβ levels by altering Aβ clearance, implicating synaptic activity with clearance mechanisms.
This is the first instance of a synaptic activity-related process regulating Aβ clearance as opposed
62

to Aβ production. These findings highlight the complexity behind the overlapping pathways
regulating extracellular Aβ levels.

MATERIALS AND METHODS
Animals
The mice used for these studies were hemizygous APPswe/PS1ΔE9 (APP/PS1; Jankowsky et al.,
2001, 2004) and bred on a wild-type C3H/B6 background or littermate controls (WT). Original
transgenic breeders were purchased from Jackson Laboratory (Bar Harbor, Maine), and colonies
were maintained at Washington University. Equal numbers of male and female mice were used
in each study at 2-4 months of age. All studies were performed in accordance with the guidelines
of AAALAC and the Institutional Animal Care and Use Committee (IACUC) at Washington
University.

Aβ Microdialysis
In vivo microdialysis was performed in awake and behaving APP/PS1 mice as previously
described (Cirrito et al., 2003, 2011). Briefly, guide cannulas (BR-style, Bioanalytical Systems,
West Lafayette, IN) were stereotaxically implanted above the left hippocampus, coordinates
bregma -3.1mm, 2.5mm lateral to midline, and 1.2mm below dura at a 12° angle. The cannulas
were securely affixed to the head with dental cement, and microdialysis probes (BR-2, 2mm,
38kDa MWCO, Bioanalytical Systems) were inserted into the hippocampus through the guide
cannula. In APP/PS1 mice, probes were perfused with artificial cerebrospinal fluid (aCSF;
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1.3mM CaCl2, 1.2mM MgSO4, 3mM KCl, 04mM KH2PO4, 25mM NaHCO3, and 122mM NaCl,
pH 7.35) with 0.15% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO) at a rate of
1.0µL/min with samples of hippocampal ISF collected every 90 minutes during basal collection
or every hour during treatment. Because WT murine Aβ concentrations are lower than in
transgenic mice, microdialysis was run at 0.5µL/min and samples collected every 3 hours to
increase concentration of each sample. Basal sampling began at least 16 hours following surgery.
These experiments took place under constant light conditions to diminish circadian-related
fluctuation in Aβ levels. At the conclusion of the experiment, all ISF samples were analyzed for
Aβx-40 or Aβx-42 levels by sandwich ELISA.

Compounds
Reverse microdialysis was used to administer compounds directly into the hippocampus. Drugs
were diluted into the perfusion buffer of artificial CSF and 0.15% BSA, allowing the drugs to
diffuse into the brain continuously for the duration of the experiment at the same time that Aβ is
collected. Due to the complexity of determining the final concentration of compound delivered to
the brain, only the starting concentrations of drugs in the perfusion buffer are given. We estimate
approximately 10% of the drug is delivered across the probe membrane where it is further
diluted in the brain CSF. AMPA (0.5, 2, 5, and 10µM), MK801 (100µM), NMDA (40µM), and
thiorphan (10µM) were purchased from Sigma. Cyclothiazide (CTZ; 300µM), FK506 (10mg/kg),
CP-465022 (2, 5mg/kg), tetrodotoxin (TTX; 5µM), NBQX (100µM), and GM6001 (25µM) were
purchased from Tocris Bioscience (Ellisville, MO). LY411575 (Sigma) was diluted in corn oil
and administered subcutaneously at 5 mg/kg. FK506 was serially diluted in DMSO then
propylene glycol and administered subcutaneously at 10mg/kg. CP-465022 was diluted in water
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and administered at both 2- and 5mg/kg subcutaneously. Recombinant mouse IL-6 protein was
obtained from Millipore Sigma (Temecula, CA). Recombinant hexafluoroisopropanol (HFIP)Aβ40 was purchased from rPeptide and reconstituted in DMSO.

Aβ Sandwich ELISAs
ISF samples were analyzed for Aβx-40 or Aβx-42 concentration using methods previously
described (Fisher et al., 2016). A mouse monoclonal anti-Aβ40 capture antibody (mHJ2) or antiAβ42 capture antibody (mHJ7.4) made in-house was used in conjunction with a biotinylated
central domain detection antibody (mHJ5.1) and streptavidin-poly-HRP-40 (Fitzgerald
Industries, Acton, MA). Super Slow ELISA TMB (Sigma) was then used to develop, and
absorbance was read by a BioTek Epoch plate reader at 650 nm. The same assay can be used for
both human and murine Aβx-40. Standard curves for ELISAs were generated using synthetic
human Aβ40 or Aβ42 (American Peptide, Sunnyvale, CA). Basal levels of ISF Aβ levels were
calculated by averaging the Aβ concentrations taken every 90 minutes for 9 hours prior to drug
treatment. All Aβ levels for each mouse were then normalized by calculating percent of basal for
each point. Mean ± SEM per group are shown.

Western blotting
Guide cannula implantation and microdialysis were performed as described above using 2-4
month old APP/PS1 mice. 5µM AMPA or vehicle was administered to APP/PS1 mice via
reverse microdialysis for 8 or 14 hours. Immediately following treatment, perfusion buffer was
changed to aCSF containing 0.1% Evans Blue dye for 30 minutes. During this period, the area of
the hippocampus directly surrounding the microdialysis probe was dyed blue, approximating the
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area of tissue affected by reverse microdialysis drug delivery. Following the 30-minutes of Evans
Blue administration, the mice were sacrificed and the dyed tissue surrounding the probe was
microdissected and snap frozen on dry ice, generating approximately 5-7mg of tissue per mouse.
The collected hippocampal tissue was homogenized by sonication at a 10:1 volume:wet weight
in 150mM NaCl, 50mM Tris, pH 7.4, 0.5% deoxycholic acid, 0.1% SDS, 1% Triton X-100,
2.5mM EDTA, and protease inhibitors. Gel electrophoresis of 20µg protein samples was
performed under reducing conditions using 4-12% Bis-Tris NuPAGE gels (ThermoFisher
Scientific, Waltham, MA) and then transferred to nitrocellulose membrane. Blots were probed
for glial fibrillary acidic protein (GFAP; 1:500; ThermoFisher), low density lipoprotein receptorrelated protein 1 (LRP1; 1:5000; Abcam, Cambridge, MA), insulin-degrading enzyme (IDE;
1ug/mL; Abcam), neprilysin (1:1000; Millipore), matrix metalloproteinase-9 (MMP-9; 1:1000;
Millipore, Billerica, MA), C-terminal fragments of APP (1:1000; Sigma), β-amyloid 1-16 (6E10;
1:500; BioLegend, San Diego, CA), glutamate receptor 2 (GluR2; 1:1000; Millipore), tubulin
(1:2500; Sigma), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1:10,000; Sigma).
HRP-conjugated goat anti-rabbit IgG (1:1000; Cell Signaling Technology, Danvers, MA) and
HRP-conjugated Amersham ECL sheep anti-mouse IgG (1:500; GE Healthcare, Chicago, IL)
were used as secondary antibodies. Membranes were developed using SuperSignal West Pico
Substrate (ThermoFisher) or Lumigen-TMA6 (GE Healthcare) and imaged using the Kodak
ImageStation 440CF (Rochester, NY). Band intensity was quantified using the Kodak 1D Image
Analysis software, and normalized using tubulin or GAPDH signals as loading controls. Values
shown are these normalized band intensities relative to the experimental control group. Mean ±
SEM per group are shown.
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Quantitative Real-Time PCR (qPCR)
Using the same tissue preparation as used for Western blotting (described above), APP/PS1 mice
were treated with 5µM AMPA for 8 or 14 hours, followed by 30 minutes of 0.1% Evans Blue
solution via reverse microdialysis. Dyed tissue around the probe was microdissected and frozen.
Quantitative PCR was performed as described previously (Fisher et al., 2016). The RNeasy Mini
Kit (Qiagen, Valencia, CA) was used to extract RNA, which was then reverse transcribed with a
High Capacity cDNA Reverse Transcription kit (ThermoFisher). The Harvard Medical School
Primer Bank was used to design primers (Wang and Seed, 2003; Spandidos et al., 2008, 2010).
Real-time detection of PCR product was performed using the Fast SYBR Green Master Mix
(Applied Biosystems, Foster City, CA) in ABI 7900HT (Applied Biosystems) with the default
thermal cycling program. cFos was used as a positive control due to its established role as a mark
of neuronal activity (Kaczmarek, 1993). Gapdh was used as a reference gene for relative
expression calculations. Relative mRNA levels were calculated using the comparative Ct method
using the formula 2-ΔΔCt. Mean ± SEM per group are shown.

Histology
2-4 month-old wild-type mice (n=6 per group) or APP/PS1 mice (n=3 per group) were treated
with 8 hours or 14 hours, respectively, of AMPA or artificial CSF via reverse microdialysis then
immediately transcardially perfused with ice-cold phosphate buffer saline (PBS) with 0.3%
heparin. Brains were removed, fixed in 4% paraformaldehyde for 24 hours at 4°C, then placed in
30% sucrose prior to freezing and sectioning. Coronal brain sections 50µm wide were sliced in
300µm intervals using a freezing sliding microtome. Sections were then immunostained to
67

visualize astrocytes or microglia using antibodies against glial fibrillary acidic protein (GFAP;
1:500, ThermoFisher) as an astrocytic marker or against ionized calcium-binding adaptor
molecule 1 (Iba1; 1:500; Wako Laboratory Chemicals, Richmond, VA) as a microglial marker.
Biotinylated secondary antibody, horseradish peroxidase-conjugated streptavidin, and DAB
reaction (Sigma) were used to develop. Brain sections were imaged with a Nanozoomer slide
scanner (Hamamatsu Photonics, Bridgewater, NJ). Staining density was qualitatively evaluated
by blinded observers and vehicle- and AMPA-treated groups were compared. Images shown are
representative.

Aβ Elimination Half-Life
Half-life of ISF Aβ was measured using methods described previously (Cirrito et al., 2003).
Microdialysis was performed as detailed above and basal ISF Aβ levels were collected. Reverse
microdialysis was then used to treat APP/PS1 mice with either 5µM AMPA or vehicle for 14
hours, followed by co-administration with LY411575, a potent and selective γ-secretase inhibitor
(Sigma; 5mg/kg in corn oil, subcutaneous injection) to block Aβ production. ISF Aβ levels were
measured using sandwich ELISA, and the half-life was calculated using the slope of the semi-log
plot of percent change in Aβ levels versus time. The slope was calculated based only on Aβ
values that were continually decreasing, excluding points at which levels plateaued. Mean ±
SEM per group are shown.

Aβ Uptake Assay
BV2 microglial cell line was generously provided by Kristen Funk (Washington University in St.
Louis, St. Louis, MO) and cultured in DMEM supplemented with 2% FBS. Cultures were
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maintained in at 5% CO2 humidified atmosphere of 37°C. BV2 cells were plated at a
concentration of 1X105cells/mL in 12-well plates. Cells were treated with either AMPA (0.125µM) or murine IL-6 (2-25ng) for 14 hours followed by 4 hours of co-treatment with 500nM
HFIP-Aβ40 added directly to the medium. The cells were then washed 3 times with PBS,
trypsinized, and lysed in RIPA buffer, and sonicated. The concentration of Aβ40 was then
quantified via ELISA.

MesoScale Discovery (MSD) Multiplex Cytokine Assay
Hippocampal tissue was collected from APP/PS1 mice treated with either vehicle (n=7) or
AMPA (n=-9) for 14 hours via reverse microdialysis. Only tissue directly surrounding the probe
was used. Tissue was homogenized following the manufacturer protocol in 500mM NaCl, 50mM
Tris, pH 7.4, 0.5% deoxycholic acid, 0.1% SDS, 1% Triton X-100, 2mM EDTA, and protease
inhibitors (MesoScale Discovery, Rockville, MD, USA). Samples were assayed for interleukin
(IL)-1β, IL-6, and tumor necrosis factor (TNF)-α using a custom MSD Proinflammatory Panel
multiplex assay using the manufacturer’s protocol. Samples were assayed duplicate. Data
analysis was performed using MSD Workbench software.

Experimental Design and Statistical Analysis
Mice were randomly assigned into treatment groups, with equal numbers of male and females. In
addition, littermates were split between groups. Based on power analyses for detecting changes
in ISF Aβ in microdialysis experiments, we used n=4-8 mice per treatment group. A full
description of statistical tests and the number of mice used can be found in the figure legends.
Two-tailed unpaired t-tests were used to compare between two groups. One-way or two-way
69

ANOVA was used when comparing one or two independent variables, respectively, between
multiple groups. The appropriate correction for multiple comparisons was used (Sidak, Tukey, or
Bonferroni; refer to figure legends). Analysis of microdialysis experiments was performed by
averaging the final three data points of a specific treatment period and using one-way or two-way
ANOVA with an appropriate correction for multiple comparisons. Values were accepted as
significant is p≤0.05. Data in figures are presented as mean ± SEM. Prism 6.0b for Mac OS X
(GraphPad, San Diego, CA) was used for all statistical analyses.

RESULTS
Local administration of AMPA decreases ISF Aβ in a dose-dependent manner
Both synaptic activity and NMDA-Rs have distinct, established roles in regulating Aβ,
but the involvement of AMPA-R signaling in Aβ regulation has been largely unexplored. To
address this, we used in vivo microdialysis to measure the concentration of ISF Aβ in the
hippocampus of mice (Cirrito et al., 2003, 2008). Crucially, this technique allows us to monitor
changes in ISF Aβ levels over time in freely moving mice with functional glutamatergic
synapses and intact neuronal networks. Through reverse microdialysis, we are also able to
locally and continuously deliver small-molecule compounds, such as AMPA, into the
hippocampus without needing to cross the blood-brain barrier.
Using microdialysis in the hippocampus of young, plaque-free (2-4 month old)
APPswe/PS1Δe9 hemizygous (APP/PS1) mice (Jankowsky et al., 2001, 2004), we collected
hourly samples of ISF while infusing AMPA in increasing concentrations from 0.5µM to 10µM
for 8 hours each (Fig. 3.1A). AMPA delivered at 0.5µM or 2µM had no effect on ISF Aβ.
However, beginning with the 5µM AMPA concentration, ISF Aβ levels gradually decreased over
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time before stabilizing at a 32% decrease from baseline levels. An even greater decrease is seen
following 10µM AMPA treatment, with levels of Aβ stabilizing at a 75% decrease from baseline
levels (Fig. 3.1A). In the following experiments, we used 5µM AMPA in order to observe both
increases and decreases in ISF Aβ levels following AMPA treatment. 5µM AMPA decreases ISF
Aβ42 similarly to Aβ40, indicating that AMPA acts on both species of Aβ in the same manner
(Fig. 3.1B). Next, wild-type (WT) mice were treated with 5µM AMPA to eliminate potential
confounds due to the transgenes in APP/PS1 mice. Murine ISF Aβ levels in WT animals reacted
to 5µM AMPA treatment similarly to APP/PS1 mice with a 45% decrease from baseline levels
(Fig. 3.1C).
AMPA-Rs rapidly desensitize following AMPA or glutamate exposure (Trussell et al.,
1993). One possible explanation for the observed effect on ISF Aβ, therefore, could be reduced
activity due to decreased AMPA-R signaling. To test this possibility, we treated the APP/PS1
mice with cyclothiazide (CTZ), a thiazide diuretic, which inhibits desensitization and potentiates
AMPA-mediated glutamate currents (Yamada and Rothman, 1992). The mice were pre-treated
with CTZ for 4 hours before and then during treatment with increasing doses of AMPA (0.5µM5µM) lasting four hours each (Fig. 3.1D). Potentiated AMPA-R signaling enhanced the
suppression in ISF Aβ levels with AMPA treatment starting at just 0.5µM, a dose that had no
effect on ISF Aβ without CTZ. This decrease is dose-dependent, with a maximal decrease in ISF
Aβ of 83% from basal levels (Fig. 3.1D). These data indicate that the observed decrease in ISF
Aβ is due to AMPA-R activity and not desensitization. Along with desensitization, decreased
AMPA-R signaling and resulting reduced activity could be caused by AMPA-R internalization
following excessive AMPA exposure, as is observed in LTD. One of the key phosphatases
identified for receptor dephosphorylation and subsequent endocytosis is calcineurin, also known
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as protein phosphatase 2B (Mulkey et al., 1994; Beattie et al., 2000). To determine if AMPA
treatment causes calcineurin-mediated AMPA-R internalization, we pre-treated APP/PS1 mice
with FK506, a calcineurin inhibitor, before co-treating with 5µM AMPA (Fig. 3.1E). Calcineurin
inhibition did not block the decrease in ISF Aβ caused by AMPA exposure, suggesting that loss
of AMPA-R signaling through endocytosis is not responsible for the effect of AMPA on Aβ. It is
important to note, however, that calcineurin is likely not the only signaling molecule regulating
AMPA-R internalization.

AMPA decreases Aβ levels through multiple distinct pathways
The exogenous application of AMPA through reverse microdialysis allows us to directly
and selectively target AMPA-Rs. However, infusion of AMPA does not necessarily reproduce
endogenous AMPA-R signaling. To address this, we treated mice with NBQX, a competitive
AMPA-R antagonist (Fig. 3.2A). When baseline levels of AMPA-R signaling were blocked, ISF
Aβ levels decreased by 32%, suggesting that AMPA-R activation increases Aβ during normal
activity. To confirm these results, we also used a non-competitive AMPA-R antagonist, CP465022. As with the competitive antagonist, ISF Aβ levels decreased by approximately 32%
(Fig. 3.2B).
Next, we treated mice with tetrodotoxin (TTX) for 16 hours to prevent the production of
action potentials and therefore block evoked presynaptic release of glutamate (Fig. 3.2C).
Following 16 hours of TTX treatment, we co-infused TTX with NBQX. As previously reported,
treatment with TTX alone decreased ISF Aβ levels by about 40% from basal levels (Cirrito et al.,
2005b). Blocking AMPA-Rs in addition to TTX treatment lead to a further decrease in Aβ levels
of 33% despite the cessation of presynaptic activity (Fig. 3.2C). Thus, AMPA-R signaling
72

mediated by receptors activated during steady-state, tonic levels of activity appears to normally
repress ISF Aβ levels independently of evoked glutamatergic signaling. Interestingly,
antagonizing basally active AMPA-Rs induced a full effect on ISF Aβ levels regardless if action
potentials were intact or blocked with TTX, suggesting that basal AMPA-ergic regulation of Aβ
is driven by spontaneous glutamate release via miniature EPSCs (“minis”) as opposed to evoked
activity.
We next determined the extent to which AMPA-mediated Aβ regulation relies on
presynaptic activity. As before, mice were pre-treated with TTX followed by co-treatment with
TTX and AMPA. During the initial 8 hours of TTX and AMPA treatment, the decrease in Aβ
levels caused by AMPA treatment (Fig. 3.2D) was abolished. However, a longer AMPA
treatment of 14 hours significantly decreased ISF Aβ levels by 30% of post-TTX levels (Fig.
3.2C). These results imply that, initially, evoked glutamatergic transmission is necessary for
AMPA treatment to decrease ISF Aβ. With longer treatment, however, ISF Aβ levels are reduced
through postsynaptic AMPA-R signaling alone, without the need of action potentials or further
glutamatergic activity stimulation.
Given that high levels of NMDA-R activation result in decreased Aβ levels through
calcium–dependent ERK signaling (Hoey et al., 2009; Verges et al., 2011), we hypothesized that
AMPA treatment might reduce ISF Aβ levels through the indirect activation of NMDA-Rs
expressed on downstream postsynaptic neurons. To determine the contribution of NMDA-Rs to
the changes in Aβ levels following AMPA treatment, mice were pre-treated with MK801, an
NMDA-R open channel blocker, via reverse microdialysis for 6 hours before co-treatment with
MK801 and 5µM AMPA (Fig. 3.2E). Initially, co-application of MK801 and AMPA did not
show an AMPA-related change in Aβ levels. However, after 8 hours of AMPA administration
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Aβ levels began to decline, reaching 50% by hour 14 (Fig. 3.2E). These data imply that AMPA’s
effects on ISF Aβ levels are dependent on NMDA-R signaling for only a limited period. After
prolonged treatment with AMPA, Aβ levels are decreased through a NMDA-R-independent
mechanism.
In consideration of these results, we questioned if AMPA-R signaling might be
responsible for any part of NMDA-Rs’ effect on Aβ levels. To test this, we first treated the mice
with 100µM NBQX, a competitive AMPA-R antagonist, through reverse microdialysis then cotreated with NMDA (Fig. 3.2A). As observed in previous experiments (Verges et al., 2011),
40µM NMDA reduced ISF Aβ levels to approximately 50% of basal levels within 6 hours of
treatment, even in the presence of an AMPA-R antagonist (Fig. 3.2A). Though the effect of
AMPA treatment on ISF Aβ in part relies on NMDA-R involvement, the opposite does not
appear true; NMDA treatment decreases Aβ levels independently from AMPA-R activation. To
ensure the specificity of AMPA treatment, animals were treated with NBQX to block AMPA-Rs
prior to the addition of AMPA. As was expected, NBQX completely blocked the effect of
AMPA-Rs on Aβ (Fig. 3.2A).

AMPA treatment results in long-lasting changes in ISF Aβ levels
Previous data show that activation of NMDA-R signaling rapidly decreases ISF Aβ levels
by approximately 50% (Verges et al., 2011). Once NMDA is no longer administered, ISF Aβ
gradually returns to baseline levels within 30 hours. AMPA treatment, however, results in a
longer-lasting change in Aβ levels. APP/PS1 mice were treated with 5µM AMPA in the
microdialysis perfusion buffer for 8 hours. After this period, AMPA treatment ended and Aβ
levels were monitored every 1-2 hours for an additional 44 hours (Fig. 3.3A). Levels of ISF Aβ
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decreased steadily during the AMPA treatment and continued to decrease for 3 hours into the
washout period to reach a maximal decrease of 60% from basal levels. From this trough, Aβ
levels very gradually increased for the duration of the washout, reaching a level only 35%
decreased from basal levels after 44 hours of recovery (Fig. 3.3A). The washout study was
terminated after a total of 60 hours of ISF collection due to limitations in the reliable duration of
microdialysis experiments, so it is possible that Aβ levels may completely recover from AMPA
treatment with a longer washout period. A recovery in ISF Aβ suggests that AMPA treatment
does not cause major cell death and that the area surrounding the microdialysis probe continues
to function normally following treatment.
APP/PS1 mice were treated with AMPA for 8 hours followed by co-administration with
NBQX (Fig. 3.3B). The decrease in Aβ levels following AMPA application did not recover to
baseline levels with the addition of NBQX despite the cessation of AMPA-R activation.
Because the Aβ decrease was preserved without AMPA-ergic transmission, the effect on Aβ is
likely due to a long-lasting intracellular event and not a feed-forward increase in continued
glutamatergic transmission. This observed long-lived change in Aβ levels was initiated by an
AMPA treatment period of only 30 minutes, which resulted in a 30% decrease in ISF Aβ (Fig.
3.3C).

Transcription of APP processing-related genes and the levels of APP fragments are
unchanged following AMPA treatment
We demonstrated above that extended treatment with AMPA influences ISF Aβ levels
without the need for NMDA-R activation. NMDA-Rs are often associated with intracellular
signaling and transcriptional regulation, while AMPA-Rs are generally thought of in terms of
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neuronal depolarization. However, there is growing evidence to suggest that AMPA-Rs may also
play an active role in cellular signaling. For example, Plant et al. (2006) found that transient
calcium signaling through calcium-permeable AMPA-Rs promotes the maintenance of long-term
potentiation (LTP). Additionally, AMPA-R signaling, independent of depolarization, is sufficient
to activate the transcription factor CREB as well as to initiate ERK signaling (Perkinton et al.,
1999b; Santos et al., 2006; Rao and Finkbeiner, 2007). Given these results, the AMPA-Rdependent decrease in ISF Aβ that we observe could be due to the initiation of a signaling
cascade by AMPA-Rs. First, we tested if AMPA-Rs affect the transcription of genes related to
APP processing or Aβ clearance (Fig. 3.4A,B). APP/PS1 mice were administered 5µM AMPA
for 8 or 14 hours by reverse microdialysis. At the end of treatment, probes were infused with
Evans Blue for 30-minutes to mark the surrounding tissue reached by reverse microdialysis. The
dyed hippocampal tissue was lysed and used for quantitative real-time PCR (qPCR) for a
selection of genes involved in Aβ metabolism. Expression of the immediate early gene, cFos,
was used as a control due to its increased expression following glutamatergic transmission
(Kaczmarek, 1993). As expected, AMPA treatment increased the expression of cFos in both the
8- and 14-hour groups. However, we found no significant changes in the expression of APP, in
genes related to α-secretase (ADAM10 and ADAM17), in genes related to β-secretase (BACE1),
nor in genes related to ϒ-secretase (PS1, PS2, PSEN2, APH1, BSG, and NIC) following 8 or 14
hours of AMPA treatment (Fig. 3.4A,B). Further, AMPA treatment did not change expression in
ERK1 or ERK2 or in genes associated with Aβ clearance (LRP1, LRPR, AQP4, NEP, MMP2, and
MMP9). Finally, none of the AMPA-R subunits genes (GRIA1-4) were altered by AMPA
treatment (Fig. 3.4A,B).
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Extended treatment with AMPA promotes increased ISF Aβ clearance but not Aβ
production
To the best of our knowledge, all previous studies investigating the relationship between
synaptic signaling and alterations in Aβ levels, including several from our laboratory, have found
that synaptic signaling primarily affects Aβ production (Cirrito et al. 2003; Cirrito et al. 2005;
Fisher et al. 2016; Kamenetz et al. 2003; Bero et al. 2011; Yan et al. 2009; Wei et al. 2010).
However, after 14 hours of AMPA administration, we found no change in full-length APP levels
or in the cleavage product β-C-terminal fragment (β-CTF) as determined by Western blot (Fig.
3.5A). In combination with the lack of transcriptional changes in production-related genes (Fig.
3.4A,B), these data lead us to hypothesize that extended treatment with AMPA could regulate
Aβ clearance.
Aβ is eliminated from the ISF through five main pathways: receptor-mediated transport
across the blood brain barrier (BBB), enzymatic degradation, cellular uptake, glymphaticmediated clearance, or passive bulk-flow clearance (for reviews see Tanzi et al., 2004; Holtzman
et al., 2011; Tarasoff-Conway et al., 2015). If any of these pathways is targeted by AMPA
treatment, the rate of ISF Aβ clearance could increase. To test this possibility, we measured halflife of ISF Aβ in mice treated with either 5µM AMPA or vehicle using reverse microdialysis
(Fig. 3.5B,C). After 14 hours, mice were subcutaneously injected with LY411575, a potent γsecretase inhibitor that rapidly inhibits Aβ production. LY411575 enters the brain and within 15
minutes reaches a concentration approximately 200-fold in excess of its IC50 for γ-secretase
inhibition (Cirrito et al., 2003). The rate of decrease in Aβ levels was then measured for both
groups using the slope of the semi-log plot of percentage baseline Aβ levels versus time (Fig.
3.5C). Interestingly, the half-life of ISF Aβ was significantly shorter by over 30% in mice
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receiving AMPA treatment (t1/2= 0.93 hr) than those in the control group (t1/2= 1.38 hr),
indicating that AMPA treatment increases the clearance of ISF Aβ (Fig. 3.5D). It is important to
note that 6 of 12 AMPA-treated mice had ISF Aβ levels decrease so much that a reliable half-life
could not be calculated. If this greater decrease following AMPA treatment was also due to
enhanced clearance, then the observed significance of AMPA on Aβ elimination rate would be
enhanced, meaning we could be underestimating the effect of AMPA on Aβ clearance.
Next, we measured the levels of key proteins involved in Aβ clearance in the
hippocampal tissue surrounding the microdialysis probe for mice treated with 14 hours of AMPA
or vehicle (Fig. 3.6A). Similar to the qPCR experiments (Fig. 3.4B), only the positive control
cFos showed a significant change in protein levels with AMPA treatment (Fig. 3.6A). Though
these data suggest that none of the Aβ clearance-related proteins selected is involved in AMPAmediated regulation of Aβ, Western blots do not detect cell type-specific changes in protein
levels, alterations in protein function, or changes in protein localization. To test if AMPA
treatment increases protease activity and thus Aβ degradation, we pre-treated APP/PS1 mice
with the neprilysin inhibitor, thiorphan, or with the broad-spectrum metalloproteinase (MMP)
inhibitor, GM6001, before co-treating with AMPA. Inhibition of neprilysin or all MMP family
members blocks Aβ clearance pathways as well as potentially inhibits α-secretase, which
increases ISF Aβ levels when those agents are administered singly (Fig. 3.6B). Importantly, the
addition of AMPA still decreased Aβ by a comparable amount as observed without protease
inhibitors, indicating that AMPA does not affect proteolytic degradation of Aβ through these
proteases.
Another possible clearance route is the uptake of extracellular Aβ by microglial
phagocytosis. We utilized a BV2 cell culture model to test the effect of AMPA treatment on
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microglial Aβ uptake (Fig. 3.6C). BV2 cells are retroviral immortalized mouse microglial cells
that share many similar functions with primary microglia (Bocchini et al., 1992; Henn et al.,
2009; Stansley et al., 2012). These cells were treated with various concentrations of AMPA,
ranging from 01µM to 25µM, for 14 hours followed by 4 hours of treatment with synthetic Aβ40
(500nM). The cells were thoroughly washed, trypsinized to digest surface-bound Aβ, and lysed
for intracellular Aβ quantification. No change in the amount of Aβ taken up by the BV2 cells
was observed following AMPA treatment of any concentration. While these data suggest that
AMPA treatment does not directly affect microglial phagocytosis of Aβ, there are a number of
caveats. For instance, AMPA treatment could be affecting clearance by acting on multiple cell
types, including microglia. Additionally, BV2 cells do not exhibit the same degree of activation
following stimulation as primary microglia (Stansley et al., 2012).

AMPA-R activation does not induce inflammation
A potential concern is that AMPA treatment decreases ISF Aβ by causing cellular
toxicity and/or creating a lesion through increased glutamatergic activity (Olney et al., 1986). If
AMPA does cause cellular damage, an inflammatory response would involve the recruitment and
activation of microglia and astrocytes (Eng et al., 1992; Denes et al., 2007; Hanisch and
Kettenmann, 2007). To monitor inflammatory responses, mice were treated with 5µM AMPA or
with vehicle for 8 or 14 hours before brains were collected and fixed in 4% formaldehyde. The
brains were stained for Iba1, a marker of microglia (Ito et al., 2001), and GFAP, a marker for
astrocytes (Bush et al. 1999; Eng et al. 1992). As expected, we found increased Iba1 and GFAP
staining around the microdialysis probe tract, but no change in staining density between the
AMPA-treated and vehicle-treated tissue at either time point (Fig. 3.7A). For confirmation, we
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measured protein levels of GFAP and CD45, another microglial marker (Bennett et al. 2016),
using hippocampal lysates from APP/PS1 mice treated with either 5µM AMPA or vehicle for 14
hours (Fig. 3.7B). In agreement with the immunostaining results, AMPA treatment did not
increase GFAP or CD45 protein levels, indicating a lack of glial recruitment (Fig. 3.7B). In
addition to monitoring the glial response, we measured pro-inflammatory cytokines levels in the
hippocampal lysates of mice following AMPA treatment. Though IL-1β and TNF-α levels were
unchanged, the levels of IL-6 showed a dramatic increase of over 500% (Fig. 3.7C). IL-6 is a
neuropoietic cytokine with both neuromodulatory and neuroprotective roles, known to be
induced by neuronal activity (Sallmann et al., 2000; Juttler et al., 2002; Erta et al., 2012).
Without a visible increase in gliosis and with no significant increase in IL-1β or TNF-α, there
does not appear to be a broad inflammatory response. These data, along with the partial recovery
of ISF Aβ in the 44 hours sampled following AMPA treatment (Fig. 3.3A), strongly suggest
AMPA is not causing widespread toxicity accounting for the effects on Aβ observed in these
experiments.

DISCUSSION
In this study, we provide evidence that evoked AMPA-R signaling decreases extracellular
Aβ concentration through two different pathways. The first of these pathways acts on Aβ through
an indirect network effect; AMPA-R stimulation leads to increased glutamatergic transmission,
including elevated NMDA-R signaling on the postsynaptic neuron. It has been previously shown
that NMDA-Rs regulate Aβ levels by using calcium as a second messenger to activate ERK and
increase α-secretase activity. Second, we found that AMPA-Rs can also influence Aβ levels
independently of NMDA-Rs. This purely AMPA-R-mediated pathway takes longer to recruit and
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increases the rate of ISF Aβ clearance. Gene expression and protein levels of many primary
clearance-related molecules remain unchanged, possibly indicating cell-type specific changes or
alterations in protein function or localization. This is obviously an important area for future
study.

Exogenous application of AMPA decreases ISF Aβ through postsynaptic signaling
We found that infusion of AMPA directly into the hippocampus of APP/PS1 mice
through reverse microdialysis decreases ISF Aβ levels by up to 75% following the maximal dose
of 10µM. Treatment with AMPA induces a potent, long-lasting effect on Aβ levels, with even a
brief application initiating a full response. AMPA-Rs, therefore, appear to be significant
regulators of Aβ levels in the extracellular space. Factors that influence extracellular levels of Aβ
have the potential to directly influence AD pathogenesis by altering the likelihood of Aβ to
aggregate (Lomakin et al., 1997). That AMPA increases activity but suppresses Aβ levels is
somewhat surprising considering previous reports that synaptic activity drives production of Aβ.
Treatment with the GABAA receptor antagonist picrotoxin, high levels of potassium chloride, or
electrical stimulation promotes Aβ secretion into the extracellular space (Kamenetz et al., 2003;
Cirrito et al., 2005b, 2008). In a more physiological setting, increasing activity within the barrel
cortex through vibrissal stimulation results in higher levels of ISF Aβ in APP/PS1 mice
(Tampellini et al., 2010a; Bero et al., 2011). In humans, the highest levels of amyloid deposition
are found in brain regions with the highest baseline metabolic activity (Buckner et al., 2005).
Considering these findings, it would be reasonable to hypothesize that AMPA-Rs, as
excitatory channels, should increase Aβ levels. Paradoxically, however, we found increasing
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AMPA-R activation through exogenous AMPA treatment significantly decreases ISF Aβ.
Because AMPA-Rs are susceptible to rapid desensitization, we considered the possibility that
AMPA-Rs act on Aβ levels through induced synaptic depression (Yamada and Rothman, 1992;
Trussell et al., 1993). However, when receptor desensitization was blocked with cyclothiazide,
the decrease in Aβ in response to AMPA was potentiated. Receptor desensitization only limited
Aβ suppression, and receptor activation is directly responsible for the reduction of Aβ levels.
Though general increases in synaptic activity upregulate Aβ production, the activation of
certain postsynaptic signaling systems can alter APP processing to yield varied effects on Aβ
levels, particularly when α-secretase is targeted and Aβ production is precluded. As mentioned
above, serotonin receptor activation decreases Aβ levels through PKA and ERK activation
(Cirrito et al., 2011; Fisher et al., 2016). The serotonin receptor illustrates the specificity
involved in Aβ regulation; only the Gs-linked receptors decrease Aβ whereas the other G-protein
coupled serotonin receptors have no effect or may even increase Aβ (Fisher et al., 2016).
Additionally, M1 muscarinic acetylcholine (mACh) receptor agonists decrease Aβ production,
and knocking out this receptor leads to increased levels of Aβ in the brain as well as increased
amyloid pathology (Jones et al., 2008; Davis et al., 2010; Fisher, 2012). Within the glutamate
receptor family, muscarinic glutamate receptor 5 has been shown to trigger Aβ production (Kim
et al., 2010; Hamilton et al., 2014), and NMDA-Rs can modulate Aβ levels bidirectionally
(Lesné et al., 2005; Hoey et al., 2009; Verges et al., 2011). Clearly, postsynaptic effects on Aβ
are varied and markedly context-specific.

82

Spontaneous and evoked AMPA-R activation differentially regulate Aβ levels
In these studies we have shown that AMPA-R regulation of Aβ levels is multifarious.
When basal AMPA-R activity is antagonized, ISF Aβ decreases by 20%. The same decrease
occurs even after action potentials are blocked and evoked synaptic transmission is inhibited,
indicating that the basal AMPA-R signaling that increases Aβ levels is likely due to spontaneous
transmission. Conversely, application of AMPA via reverse microdialysis stimulates evoked
glutamatergic transmission as well as direct AMPA-R activation. In this scenario, AMPA-R
activation decreases Aβ levels. This dual effect of AMPA-Rs depending on the mode of
transmission has been seen in various contexts. Sara and colleagues (2011) utilized a usedependent AMPA-R antagonist to show that spontaneous and evoked transmission activate
discrete populations of AMPA-Rs. Additionally, several studies have found that receptors that
respond differentially to spontaneous and evoked transmission are physically and functionally
distinct (Murphy et al., 1994; Sutton et al., 2004, 2006, 2007; Atasoy et al., 2008; Sutton and
Schuman, 2009). Intriguingly, spontaneous activity appears to suppress protein synthesis while
evoked activity stimulates translation. Another possible explanation is that the effects of AMPARs on Aβ are dependent on relative levels of AMPA-R activation. During basal transmission, a
smaller set of AMPA-Rs is active compared to the AMPA-Rs targeted by action potentials or
exogenous AMPA treatment.

Extended AMPA treatment decreases ISF Aβ half-life
Adding an additional layer of complexity, exogenous AMPA treatment appears to act on
Aβ levels through two different pathways. Within the first 8 hours of treatment, AMPA’s ability
to modulate Aβ levels is dependent on NMDA-R signaling. This pathway relies on presynaptic
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activity to increase glutamatergic transmission, thus stimulating NMDA-R activation on
downstream neurons to decrease Aβ production in these cells (Hoey et al., 2009; Verges et al.,
2011). The reverse is not true, however; AMPA-Rs do not appear to play a role in NMDA-Rmediated decreases in Aβ. Following longer periods of AMPA treatment, a novel pathway by
which AMPA-Rs influence Aβ independently of both presynaptic activity and NMDA-Rs
emerges.
As detailed above, studies regarding synaptic and postsynaptic regulation of Aβ have
primarily addressed the effects of activity on Aβ production. However, we did not detect changes
in APP processing-related gene expression or in APP fragment levels following either 8 or 14
hours of AMPA treatment. Instead, using microdialysis along with a potent inhibitor of ϒsecretase, we found that treatment with AMPA for 14 hours decreased the half-life of ISF Aβ,
implying that AMPA-Rs can modulate Aβ levels through increased clearance. However this
effect is accomplished, it does not appear to involve glial recruitment, a broad inflammatory
response, or changes in key clearance-related proteins. We did find that one proinflammatory
cytokine, IL-6, increased dramatically following AMPA treatment. IL-6 has been shown to have
both normal physiological as well as inflammatory, pathological roles in the CNS (Gadient and
Otten, 1997; Erta et al., 2012; Gruol, 2015; Wang et al., 2015) and has been shown to increase in
response to neuronal depolarization (Sallmann et al., 2000; Juttler et al., 2002). Furthermore, IL6 signaling has been linked to increased clearance of Aβ through microglial phagocytosis
(Chakrabarty et al., 2010; Wang et al., 2015). Given the substantial increase in IL-6 following
AMPA treatment, this signaling pathway clearly calls for future study.
Though both production and clearance determine the steady state levels of Aβ in the
extracellular space, late-onset AD (LOAD) is primarily characterized by dysfunctions in Aβ
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clearance (Mawuenyega et al., 2010; Tarasoff-Conway et al., 2015). In 2003, we found that ISF
Aβ half-life as measured by microdialysis is doubled in an aged APP transgenic model compared
to young animals (Cirrito et al., 2003). In human studies, metabolic labeling and CNS analysis
revealed impaired clearance rates in participants with LOAD, though Aβ production was
unaltered (Mawuenyega et al., 2010). Furthermore, many of the genetic factors associated with
LOAD are related to clearance, including APOE, CLU, CR1, and CD33. Given the evident
prominence of Aβ clearance in AD, our results highlight the importance of understanding the
ways in which synaptic activity impinges on previous clearance-related studies.

CONCLUSIONS
There are clearly numerous mechanisms that together regulate levels of Aβ. Though the
confluence of these various synaptic-mediated pathways appears to result in increased Aβ, we
propose that certain postsynaptic signaling pathways, such as those described in these studies, act
as protective mechanisms that aid in maintaining Aβ homeostasis. The failure of these Aβsuppressing pathways may contribute to the breakdown of homeostasis that ultimately results in
the build-up of pathology. Indeed, glutamatergic transmission is one of the first systems targeted
by toxic species of amyloid as the disease progresses (Olney et al., 1997; Francis, 2003; Lacor et
al., 2007; Marcello et al., 2008).
As the dominant excitatory ionotropic receptors in the brain, AMPA-Rs have the
potential to greatly influence extracellular Aβ levels and amyloid pathology. We have found that
activation of AMPA-Rs initiates a varied and complex response in which opposing pathways act
concurrently to regulate Aβ levels. Soluble, monomeric Aβ production is a normal process of
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every brain. Even those brains destined to develop AD pathology produce Aβ for decades
without formation of toxic aggregates. The point at which Aβ becomes pathogenic is likely
influenced by a number of factors, including the loss of homeostatic pathways. Identifying and
understanding how, early in our lives, Aβ levels are controlled may give us clues to disease
etiology or even prevention.

86

A

B

5µM AMPA or veh, rev md

AMPA or veh, rev md

80

**I
**I

120

60
% Basal ISF Aβ40

100

40
20

80
60
40

Vehicle
5uM AMPA

100
100

75
80

% Basal ISF Aβ42

100

50
25

0

4

8

2

5

0

10

Concentration AMPA
via rev md (µM)

Time from Treatment (hr)

D
5µM AMPA or veh, rev md

% Basal ISF Aβ40

120
100
80

****

60
40

ip
6,
FK
50
g
m
g/
k
10

Vehicle
CTZ+AMPA

100
75

120

ns

100

50
25

80

*

60

****

40

****

0

0

10

20

Time from Treatment (hr)

µM CT
Z
A
M
PA

0

AMPA

µM CT
Z
A
M
PA

Vehicle

+5

21

C
µM TZ
A
M
PA

18

**I
ns
I

8

12

20

20
0

FK

50

Time from Treatment (hr)

16

PA

4

M

0

40

6

-4

60

A

-8

80

6+

20

100

50

40

al

60

as

% Basal ISF Aβx-40

120

FK

80

B

% Basal ISF Aβx-40

AMPA

5µM

Ve

15

100

0

Vehicle

1
5u 0m
M g/k
AM g
PA FK
, r 506
ev ,
m ip
d

E

24

20

Time from Treatment (hr)

120

AMPA dose: 0.5µM 2µM

20
0

12

20

.5

20

9

16

+2

40

6

12

le

60

3

8

C
TZ

80
% Basal Murine ISF Aβ40

% Basal Murine ISF Aβ40

100

0

4

125

Vehicle
AMPA

-3

0

300µM CTZ rev md

120

-6

-4

Time from Treatment (hr)

C

0

0

-8

30
0µ
M

0

0.5

+0

-4

0

% Basal ISF Aβ40

-8

40
20

20

0

**

60

hic

% Basal ISF Aβ40

125

Vehicle
0.5μM
2µM
5µM
10µM

% Basal ISF Aβ42

120

Figure 3.1: AMPA treatment decreases levels of ISF Aβ levels. A) Varying doses of AMPA
or vehicle (artificial CSF) were administered to 2-4 month-old APP/PS1 mice via reverse
microdialysis (rev md), and changes in interstitial fluid (ISF) Aβ40 were measured using ELISA.
AMPA has a dose-dependent effect on ISF Aβ levels. Though treatment with 0.5µM and 2µM
AMPA did not alter ISF Aβ levels significantly (n=3, n=5 respectively), treatment with 5µM
AMPA decreased levels 31.7±9.5% (p=0.015, n=4, one-way ANOVA, Dunnet’s post hoc test),
and 10µM AMPA decreased levels by 73.8±12.2% (p<0.0001, n=2, , one-way ANOVA,
Dunnet’s post hoc test). B) APP/PS1 mice (n=4) were treated with 5µM AMPA for 24 hours and
ISF Aβ42 levels decreased by 37.0±9.4% (p<0.0043, two-tailed t-test). C) Wild-type, littermate
C3H/B6 mice were dosed with 5µM AMPA using rev md and levels of murine ISF Aβ40 levels
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decreased by 49.4±8.4% (p<0.0001, n=6, two-tailed t-test). D) APP/PS1 mice were treated with
300µM cyclothiazide (CTZ) for 4 hours (n=6), after which increasing doses of AMPA (0.5, 2,
and 5µM) were added to the perfusion buffer. CTZ administered alone did not change ISF Aβ
levels. Aβ levels decreased 31.9±11.1% (p=0.030, , one-way ANOVA, Dunnet’s post hoc test)
by 0.5µM AMPA, 63.6±11.1% (p<0.0001, , one-way ANOVA, Dunnet’s post hoc test) by 2µM,
and maximally decreased 83.2±11.1% (p<0.0001, , one-way ANOVA, Dunnet’s post hoc test)
when treated with 5µM AMPA. E) APP/PS1 mice (n=3) were administered FK506 (10mg/kg), a
calcineurin inhibitor, via intraperitoneal (i.p.) injection and levels of Aβ were monitored for 6
hours, followed by another i.p. injection of FK506 concurrent with AMPA treatment via reverse
microdialysis for 16 hours. Aβ levels did not significantly decrease with FK506 alone (p=0.148,
one-way ANOVA, Tukey post hoc test) but did decrease when additionally treated with AMPA
(p=0.0063, one-way ANOVA, Tukey post hoc test). Data plotted as mean ± SEM.
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Figure 3.2: AMPA treatment alters Aβ levels through multiple pathways. A) APP/PS1 mice
(n=6) were treated with 100µM NBQX, an AMPA receptor antagonist, for 8 hours then cotreated with either 40µM NMDA (n=6), 5µM AMPA (n=7), or vehicle (n=12). After 6 hours of
co-treatment with NBQX, the addition of AMPA had no effect on Aβ levels, though NMDA still
reduced Aβ by 37.5±3.3% (p<0.0001, one-way ANOVA, Bonferroni post hoc test). B) Mice
(n=6) were administered CP465022, a non-competitive AMPA-R antagonist via i.p. injection
twice while ISF Aβ was monitored. The first injection (5mg/kg) was given 4 hours before a
subsequent 2mg/kg injection. The average of the last 3 hours of treatment was significantly
reduced by 29.6±13.1% compared to the average of the last 3 hours of basal collection
89

(p=0.0475, two-tailed t-test). C) Animals (n=6 per group) were treated with 5µM tetrodotoxin
(TTX) for 16 hours then co-treated with TTX and either 5µM AMPA, 100µM NBQX, or vehicle
for an additional 14 hours. After 8 hours of co-treatment, ISF Aβ levels remained unchanged in
all groups. After 14 hours co-treatment with AMPA reduced Aβ levels by 34.6±9.9% (p=0.0027,
two-way ANOVA, Sidak post hoc test) and co-treatment with NBQX reduced levels by
32.8±9.3% (p=0.0027, two-way ANOVA, Sidak post hoc test). D) APP/PS1 mice were treated
with either 5µM AMPA (n=7) or vehicle (n=5) for 14 hours, leading to a decrease in ISF Aβ
levels of 66.3±11.8% (p=0.0001, two-way ANOVA, Sidak post hoc test). E) 100µM MK801
was administered by reverse microdialysis for 6 hours to APP/PS1 mice followed by coadministration with 5µM AMPA or vehicle, which lead to a decrease in ISF Aβ levels of
48.8±10.0% (p=0.0013; n=5, one-way ANOVA, Tukey post hoc test). Data plotted as mean ±
SEM.

90

A

Washout (perfusion buffer only), rev md
5µM AMPA or veh, rev md

Vehicle
AMPA

ns
I

100

*I

120

75

% Basal ISF Aβ40

% Basal ISF Aβ40

125

50
25
0

80
60
40
20
0

0

10

20

30

40

Trough
(11-13hr)

50

Time from Treatment (hr)

B

Vehicle
AMPA

100

Washout
(50-52hr)

100µM NBQX or veh, rev md
5µM AMPA or veh, rev md

Vehicle
AMPA+NBQX

100

50
25

100
80
60
40
20

-4

0

4

8

12

16

20

24

Time from Treatment (hr)

(a AM
t8 P
hr A
s)
A
M
PA
(a
t2 +
4h NB
rs Q
) X

0

-8

Ve
hi
cl
e

0

ns
I

120

75

% Basal ISF Aβ40

% Basal ISF Aβ40

125

C
30min 5µM AMPA or veh, rev md

% Basal ISF Aβ40

125

***

Vehicle
AMPA

100
75
50
25
0

-8

-4

0

4

8

12

16

20

24

Time from Treatment (hr)

Figure 3.3: AMPA treatment results in potent, long-lasting decreases in ISF Aβ levels that
slowly recover. A) APP/PS1 mice (n=5) were treated with 5µM AMPA using reverse
microdialysis for 8 hours resulting in a decrease in ISF Aβ levels of 32.7±3.0% from baseline.
After 8 hours, AMPA was removed from the microdialysis perfusion buffer. Aβ levels continued
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to decline for 3 hours post-treatment to reach a maximum reduction of 56.7±1.7% from baseline.
For the next 40 hours, ISF Aβ levels gradually increased. When the experiment was ended at 52
hours, ISF Aβ levels had increased 23.5±3.0% to reach 64.8±3.0% of basal levels, which was a
significant increase from the lowest Aβ levels post-treatment (p=0.0245, two-way ANOVA,
Sidak post hoc test). B) APP/PS1 mice (n=3) were treated with 5µM AMPA followed by cotreatment with AMPA and 100µM NBQX for 14 hours. The addition of NBQX did not alter the
decrease in Aβ levels caused by AMPA treatment (one-way ANOVA, Sidak post hoc test). C)
5µM AMPA was infused by rev md into APP/PS1 mice for a 30-minute period, after which the
syringe was replaced with artificial CSF for 24 hours. AMPA treatment caused a 41.30±9.45%
decrease in ISF Aβ levels in the 22-24 hours after 30-minute dosage (n=3, p=0.035, two-tailed ttest). Data plotted as mean ± SEM.
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Figure 3.4: 8 and 14 hour AMPA treatment does not alter expression of genes related to Aβ
metabolism. 5µM AMPA or vehicle was given to 2-4 month old APP/PS1 mice for 8 hours (A)
or 14 hours (B; n=6 per group) before the hippocampal tissue surrounding the microdialysis
probe was collected and analyzed with quantitative PCR. A) qPCR analysis revealed no
differences in expression for major genes involved in Aβ production and clearance between mice
treated with AMPA or vehicle. Expression of cFos, a marker for neuronal activity, increased
7.5±3.7 fold (p<0.0001, two-way ANOVA, Sidak post hoc test) for the AMPA-treated group
over cFos expression in controls, though this difference was not significant. B) After 14 hours of
AMPA treatment, expression of genes involved in Aβ processing was not changed as shown by
qPCR analysis. AMPA-treated animals showed a 14.4±1.8 fold increase in cFos expression over
controls (p<0.0001, two-way ANOVA, Sidak post hoc test). Data plotted as mean ± SEM.
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aCSF (n=8) via reverse microdialysis for 14 hours. Tissue surrounding the microdialysis probe
was analyzed via Western blot for full-length APP and β-CTF, and no significant change was
observed between treatment groups (two-way ANOVA, Sidak post hoc test). Bands were
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normalized to GAPDH and displayed relative to control. Blot images are representative
examples. B) APP/PS1 mice were treated with 14 hours of AMPA (n=6) or vehicle (n=7). With
microdialysis collection ongoing, animals were administered a 4mg/kg subcutaneous (s.c.)
injection of LY411575, a ϒ-secretase inhibitor, or vehicle (corn oil). C) The log of the last three
microdialysis samples collected following LY411575 treatment were plotted in order to calculate
ISF Aβ half-life. D) ISF Aβ half-life for each treatment group was calculated by taking the slope
of the semi-log plot of concentration versus time for the time points between drug delivery and
the plateauing of Aβ concentrations. Mice treated with 5µM AMPA had an Aβ half-life of
0.9±0.1 hours compared to a half-life of 1.5±0.2 hours for the mice treated with aCSF (p=0.0298,
two-tailed t-test). Data plotted as mean ± SEM.
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Figure 3.6: AMPA-mediated decrease in Aβ not due to changes in clearance-related
proteins or proteases. A) 2-4 month old APP/PS1 mice were treated with either 5µM AMPA
(n=6) or aCSF (n=8) via reverse microdialysis for 14 hours. Tissue surrounding the microdialysis
probe was analyzed via Western blot to determine levels of proteins involved in Aβ elimination
and clearance. Bands were normalized to GAPDH and displayed relative to control. Blot images
are representative examples. cFos protein expression was increased 2.9±0.4 fold (p<0.0001, twoway ANOVA, Sidak post hoc test) in the AMPA group compared to the controls. No other
proteins showed a significant difference between treatment groups. B) Reverse microdialysis was
used to treat APP/PS1 mice (n=7) with 10µM thiorphan (neprilysin inhibitor), 25µM GM6001
(broad-spectrum MMP inhibitor), or vehicle for 6 hours, followed by 14 hours of co-treatment
with 5µM AMPA. The Aβ concentrations in the last 3 hours of each treatment were averaged
and the differences between the end of inhibitor/vehicle treatment and after the addition of
AMPA were compared. Inhibiting protease activity with thiorphan or GM6001 did not alter the
decrease in ISF Aβ levels observed following AMPA treatment (p=0.40, one-way ANOVA,
Dunnet’s post hoc test). C) BV2 microglial cells were treated with various doses of AMPA
(0.1µM-25µM) for 14 hours, followed by a 4 hour co-incubation with AMPA and 500nM
recombinant HFIP-Aβ40. Cells were lysed and internalized Aβ was measured with ELISA.
Treatment with AMPA did not affect the amount of Aβ taken up by the BV2 cells (p=0.30, oneway ANOVA, Dunnett post hoc test). Data plotted as mean ± SEM.
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Figure 3.7: Glial recruitment unchanged and IL-6 levels enhanced following AMPA
treatment. A) Wild-type C3H/B6 mice (for the 8 hour treatment, n=6 per group) or APP/PS1
mice (for the 14 hour treatment, n=3 per group) were implanted with microdialysis probes and
treated with either 5µM AMPA or aCSF for 8 or 14 hours. Brain sections were immunostained
with DAB using anti-GFAP antibody to mark astrocytes or anti-Iba1 antibody to mark microglia.
Immunoreactivity between control and AMPA-treated sections were compared, and
representative images are shown. B) 2-4 month old APP/PS1 mice were treated with either 5µM
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AMPA (n=6) or aCSF (n=8) via reverse microdialysis for 14 hours. Tissue surrounding the
microdialysis probe was analyzed via Western blot for GFAP or CD45, markers of astrocytes
and microglia, respectively, and no difference was observed between treatment groups (two-way
ANOVA, Sidak post hoc test). Bands were normalized to GAPDH and displayed relative to
control. Blot images are representative examples. C) As in Fig. 7B, APP/PS1 mice were treated
with either 5µM AMPA (n=9) or vehicle (n=7) for 14 hours, and hippocampal lysates were
analyzed for pro-inflammatory cytokines using a MSD multiplex assay. Levels of IL-1β
(p=0.991, two-way ANOVA, Sidak post hoc test) and TNF-α (p=0.999, two-way ANOVA,
Sidak post hoc test) were unchanged. IL-6 levels were significantly elevated following AMPA
treatment, increasing from 52.3 to 773.8pg/mL (p=0.0014, two-way ANOVA, Sidak post hoc
test). D) BV2 microglial cells were treated with various doses of recombinant mouse IL-6 (225ng) for 14 hours, followed by a 4 hour co-incubation with IL-6 and 500nM recombinant HFIPAβ40. Cells were lysed and internalized Aβ was measured with ELISA. Treatment with IL-6 did
not affect the amount of Aβ taken up by the BV2 cells (p=0.352, one-way ANOVA, Dunnett
post hoc test). Data plotted as mean ± SEM.
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CONCLUSIONS
Homeostatic regulation of brain Aβ levels is of upmost importance when considering AD
pathogenesis. Disruption of any of the fine-tuned controls that constantly strive to keep Aβ in
check could tip the scales toward amyloid pathology. Synaptic activity is known to be an
important regulator of the production of Aβ, through both pre- and postsynaptic mechanisms.
Studies have found that presynaptic activity drives Aβ production while postsynaptic receptor
activation has a more nuanced role. The goal of the experiments described herein was to explore
the regulation of Aβ levels by postsynaptic glutamatergic transmission through NMDA- and
AMPA-R activity. These questions were addressed in vivo using adult APP/PS1 mouse models
of AD to maintain an intact network of connections throughout the experiments.
We sought to define the route through which high levels of NMDA-R activation leads to
decreased production of Aβ through ERK activation with the hopes of identifying a suitable
target for therapeutic intervention. We first investigated the individual contributions of the
GluN2A and GluN2B subunits of NMDA-Rs as these subunits have been found to give the
receptor unique signaling properties and cellular roles (Hardingham, 2006; Zhang and Luo,
2013). Using subunit-specific NMDA-R antagonists, we showed that blocking either type of
receptor was insufficient to prevent NMDA treatment from decreasing Aβ levels in the ISF,
which could only be accomplished by the noncompetitive NMDA-R channel blocker MK801
(Fig. 2.1). These results indicate that neither a particular receptor subunit is necessary for Aβ
regulation by NMDA-Rs nor is the activation of a full population of NMDA-Rs. Next, we used
virally driven shRNA against either ERK1 or ERK2 to knockdown expression of each ERK
isoform in the hippocampus. As with the NMDA-R subunits, we found no specificity in NMDAR regulation of Aβ levels (Fig. 2.2).
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Again in an effort to find a selective target behind the NMDA-R-mediated decrease in Aβ
production, we inhibited a number of signaling molecules known to link NMDA-R activation to
ERK phosphorylation using pharmacological antagonists. With this method, we found that
NMDA-Rs do not act on ERK and then Aβ through signaling to CaMKII, PKC, or PKA (Fig.
2.3). Though we ultimately failed to define the pathway linking NMDA-R activation to Aβ
regulation, we were able to rule out a number of possibilities that will be useful when
considering postsynaptic activity’s link to the maintenance of Aβ homeostasis.
Knowing that NMDA-Rs have the capability to largely influence Aβ levels, we turned
our attention to the study of AMPA-R activation and Aβ regulation in Chapter 3. Though we
initially hypothesized that AMPA treatment would increase Aβ levels through synaptic activityrelated, presynaptic acceleration of APP processing, we found that the regulation of Aβ by
AMPA-Rs is quite complex and involves at least three different pathways. First, endogenous
AMPA-R activity, as targeted by AMPA-R antagonism, enhanced ISF Aβ levels (Fig. 3.2A).
Again, we believed this to be due to increased activity. However, the effect was seen even after
action potentials were blocked with tetrodotoxin, ruling out this explanation (Fig. 3.2C). With
evoked neurotransmitter release prohibited, the only AMPA-Rs activation remaining to influence
Aβ levels must be caused by spontaneous release. The concept that spontaneous glutamate
release might precipitate a cellular response independent of evoked transmission is not new. In
fact, a number of studies have shown that spontaneous release can have effects distinct from
evoked release by activating spatially segregated postsynaptic targets (Sutton et al., 2006, 2007;
Atasoy et al., 2008; Sutton and Schuman, 2009; Kavalali et al., 2011; Sara et al., 2011; Kavalali,
2014). Indeed, spontaneously activated AMPA-Rs have an important role in maintaining
dendritic spine density through signaling that does not require evoked transmission (McKinney
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et al., 1999). Our results indicate that increasing Aβ levels may be another independent role for
spontaneous AMPA-ergic signaling.
The two remaining pathways we identified by which AMPA-Rs regulate Aβ levels are
the result of evoked glutamatergic transmission. Using reverse microdialysis to bath
hippocampal cells with AMPA, we found that increasing doses of AMPA decreased ISF Aβ
levels in a dose-dependent manner (Fig. 3.1A). This was managed in part by an overall increase
in glutamatergic signaling, resulting in an action potential-dependent activation of NMDA-Rs
and subsequent NMDA-R-dependent decrease in Aβ production (Fig. 3.2C,E; Verges et al.,
2011). Much of this pathway is already described in previous publications and in Chapter 2.
Downstream activation of NMDA-Rs, however, was not the only method by which AMPA
treatment decreased Aβ levels. We found that prolonged treatment with AMPA resulted in
decreased Aβ even with NMDA-Rs or action potentials blocked (Fig. 3.2C-E). Furthermore, this
decrease was shown to be the result of enhanced Aβ clearance, not decreased production as we
hypothesized. How clearance is targeted is still unanswered, although we have data to suggest
that it is not through changes in levels of clearance-related proteins (Fig. 3.6A) or through
increased proteolytic activity of neprilysin or MMPs (Fig. 3.6B).
That AMPA-R activation is capable of altering Aβ clearance is a surprising finding
because the vast majority, if not all, other studies have linked synaptic activity to the regulation
of Aβ through changes in Aβ production (Kamenetz et al., 2003; Buckner et al., 2005; Cirrito et
al., 2005b, 2008, 2011; Jones et al., 2008; Hoey et al., 2009, 2013; Bordji et al., 2010; Kim et al.,
2010; Tampellini et al., 2010b; Verges et al., 2011; Fisher, 2012; Das et al., 2013; Sheline et al.,
2014; Tampellini, 2015; Fisher et al., 2016). Amyloid-β clearance, however, has been found to
have particular importance in the etiology of late-onset AD (LOAD). Studies in both animals
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models and humans have observed impaired clearance, rather than production, with age and
disease (Cirrito et al., 2003; Mawuenyega et al., 2010; Tarasoff-Conway et al., 2015).
Furthermore, the APOEε4 allele, the strongest genetic risk factor for LOAD, is associated with
impaired Aβ clearance (Castellano et al., 2011), as are many of the lesser genetic risk factors
identified through GWAS (e.g. CD33, CLU, CR1, PICALM, and BIN1; for review see Tanzi,
2012). These data raise the interesting possibility that alterations in synaptic activity and
specifically AMPA-R signaling may be playing a role in the observed deficits in clearance that
are so prevalent in LOAD.
Because AMPA-Rs are the most numerous excitatory receptors in the brain and the major
mediators of basal excitatory transmission, their ability to enhance Aβ clearance could have
profound implications. Evidence from rodent studies suggests that AMPA-R expression
decreases with age, which could contribute to a loss of Aβ homeostasis if AMPA-R regulation
becomes dysregulated (Shi et al., 2007; Gocel and Larson, 2013; Pandey et al., 2015).
Furthermore, many studies have found that Aβ exposure downregulates AMPA-R expression,
possibly contributing to a feed-forward increase in amyloid pathology (Chang et al., 2006; Hsieh
et al., 2006; Liu et al., 2010; Miñano-Molina et al., 2011; Chater and Goda, 2014; Guntupalli et
al., 2016a). Moreover, these results could implicate AMPA-R activity and changes in Aβ
clearance to the finding that amyloid pathology is most severe in brain regions exhibiting the
highest levels of synaptic activity (Raichle et al., 2001; Buckner et al., 2005, 2009). AMPA-R
regulation of Aβ levels has the potential to significantly impact Aβ homeostasis and clearly
merits further study.
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FUTURE DIRECTIONS
When addressing such a broad topic as “glutamatergic regulation of Aβ,” there are
naturally numerous lines of study yet to be undertaken. I will describe those most pertinent to the
results discussed in this document.
NMDA-R signaling and Aβ production
In my second chapter, I described my attempts to define the signaling pathway linking
NMDA-R signaling to ERK activation and decreased Aβ production. Though I was able to
eliminate a number of possibilities, I did not manage to identify a single part of the pathway that
could act as a desirable target for therapeutics. Likely unexplored candidates by which NMDARs signal to activate ERK are Ras-specific guanine nucleotide-releasing factor 1 and 2
(RasGRF1,2), highly homologous guanine nucleotide exchange factors (GEFs), that have been
shown to directly couple NMDA-Rs to ERK (Krapivinsky et al., 2003; Tian et al., 2004;
Hardingham, 2006; Ivanov et al., 2006b; Li et al., 2006; Vantaggiato et al., 2006; Bengtson et al.,
2008; Feig, 2011). Though no pharmacological inhibitor exists for RasGRFs, the role of
RasGRF1,2 in linking NMDA-R activation to Aβ regulation could be tested by knocking down
expression of either protein using RNA interference, then monitoring the effects of NMDA
treatment on ISF Aβ levels, similar to the approach used in Fig2.2. Also available are a number
of mouse lines generated with either or both RasGRF1 or 2 deleted (Brambilla et al., 1997; Itier
et al., 1998; Giese et al., 2001; Fernández-Medarde et al., 2002; Tian et al., 2004). These mice
could be treated with NMDA to gauge if the effect on Aβ is still present without RasGRF
signaling, or they could be crossbred with APP/PS1 mice to determine the impact of the deletion
on amyloid pathology.
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Astrocytic regulation of glutamatergic transmission
Previous findings along with the results discussed herein demonstrate the roles of both
NMDA-Rs and AMPA-Rs in regulating Aβ levels. Within a functional tripartite synapse, the
amount of NMDA-R and AMPA-R activation is carefully regulated through the uptake of
glutamate from the extracellular space by astrocytes. Astrocytic function, therefore, likely plays
an important role in glutamatergic Aβ regulation. Intriguingly, studies using both AD human
tissue and AD animal models show irregular astrocytic glutamate uptake associated with amyloid
pathology (Cross et al., 1987; Scott et al., 2002; Begni et al., 2004; Matos et al., 2008).
Astrocytic uptake of glutamate is accomplished primarily through the two main astrocytic
excitatory amino acid transporters (EAATs), EEAT1 and EAAT2 (Rothstein et al., 1996; Lehre
and Danbolt, 1998). Manipulating EAAT activity either pharmacologically or genetically could
mimic the changes in astrocytic glutamate uptake observed in AD, and changes in the effects of
NMDA-R and AMPA-R activation on Aβ levels could be measured. How aberrant astrocytic
glutamate uptake affects the regulation of Aβ by both NMDA-Rs and AMPA-Rs could yield
insights into the break down of normal homeostatic mechanisms during the disease process.
AMPA-Rs, IL-6, and Aβ regulation
As described in chapter 3, we found that AMPA-R signaling enhances clearance of Aβ
from the ISF. How this process is accomplished, however, is still largely unanswered. In
searching for an inflammatory response following extended AMPA treatment, we found that
levels of the proinflammatory cytokine IL-6 were greatly increased in mice treated with AMPA
(Fig. 3.7C). Because neither IL-1β nor TNF-α were altered, AMPA appears to selectively act on
IL-6 instead of creating a mass inflammatory response. This is of interest due to studies showing
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that IL-6 signaling can increase clearance of Aβ through microglial phagocytosis (Chakrabarty et
al., 2010; Wang et al., 2015). Overexpression of IL-6 in the brains of either neonatal or adult AD
mouse models decreased plaque burden, though APP levels, APP processing, and steady-state
Aβ generation were unchanged (Chakrabarty et al., 2010). In general, activated microglia
exhibiting the M2 phenotype remove Aβ deposits from the extracellular space and have been
shown to play a beneficial role in neurodegenerative diseases (Ries and Sastre, 2016; Tang and
Le, 2016). IL-6 is known to be released in response to neuronal depolarization, explaining how
AMPA treatment might lead to its increase (Sallmann et al., 2000; Juttler et al., 2002). We
hypothesize that AMPA-R activation leads to IL-6 release, thereby stimulating microglial uptake
of Aβ from the extracellular space. We are engaged in experiments that aim to block IL-6
signaling to determine its role in AMPA-R-mediated Aβ clearance in vivo. Another approach
would be to test Aβ uptake in mixed primary cultures of both microglia and neurons in response
to AMPA treatment.
Other mechanisms of AMPA-R-mediated Aβ regulation
IL-6 signaling is not the only candidate by which AMPA-Rs alter Aβ clearance. The lowdensity lipoprotein receptor-related protein 1 (LRP1), is an endocytic receptor expressed on
neurons, vascular cells, and glia (Kanekiyo and Bu, 2014). LRP1 can directly bind Aβ and
facilitate its transport from the extracellular space. Indeed, LRP1 has been linked to neuronal Aβ
uptake (Kanekiyo et al., 2013), microglial Aβ phagocytosis (Kanekiyo et al., 2011; N’Songo et
al., 2013), astrocytic Aβ uptake (Liu et al., 2017), and transcytosis across the endothelial cells of
blood brain barrier (BBB; Deane et al., 2004; Kanekiyo et al., 2012; Storck et al., 2015). Mice
with conditional, cell-specific LRP1 deletion have been generated, and could be used to
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determine if AMPA-Rs regulate Aβ levels through LRP1 signaling. Alternatively, LRP1 binding
to Aβ could be prohibited using an LRP1 blocking antibody.
The mechanism by which Aβ is degraded once it is taken up into neurons or glial cells
has not been extensively defined. Microglial cultures can degrade phagocytosed Aβ through the
autophagic pathway (Cho et al., 2014) and require lysosomal acidification (Majumdar et al.,
2011). Lysosomal Aβ degradation has also been observed within neurons in AD animal models
(Li et al., 2012; Xiao et al., 2014, 2015). If AMPA treatment does indeed increase cellular uptake
of Aβ as we predict, then it is likely that lysosomal activity is increased following AMPA-R
activation. One method to test this hypothesis is to quantify the colocalization of lysosomal
proteins with Aβ using immunohistochemistry. Additionally, lysosomal activity could be
blocked with cathepsin inhibitors.
Finally, we found that basal levels of AMPA-R activation normally act to increase ISF
Aβ levels in the hippocampus (Fig. 3.2A,B) in a manner that does not rely on action potentials
(Fig. 3.2C). We concluded that miniature, spontaneous events must drive increased Aβ through
AMPA-R signaling. There are many follow-up questions raised by these findings. First, how do
AMPA-Rs increase Aβ, through production or clearance? Also, does the magnitude or direction
of basal AMPA-R regulation of Aβ change with age or disease status? What mediates the
opposing effects of AMPA-R activation resulting from spontaneous or evoked transmission?
Does the effect on Aβ levels simply rely on the number of AMPA-Rs activated, or is each type
of transmission acting on a specific population of receptors? Could Aβ clearance through evoked
AMPA-R signaling be simulated with the induction of long-term potentiation? The answers to
these questions would fill their own dissertation and would help us further understand the
interplay between normal brain functioning and Aβ regulation.
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CLOSING REMARKS
The loss of Aβ homeostasis is a crucial event in AD pathogenesis, occurring decades
before symptom development. As we learn more about AD pathology, a multitude of
mechanisms working to keep Aβ levels in check have become apparent, with synaptic activity
key among them. Even within this one category is a diversity of pathways. In this dissertation,
we have explored the regulation of Aβ by NMDA- and AMPA-Rs, the receptors responsible for
the majority of excitatory transmission and synaptic plasticity. By doing so, we have sought to
understand how the normal workings of the brain may slowly and subtly set the stage for the
amyloid cascade. By defining the mechanisms that constantly influence Aβ production and
clearance, we can begin to pinpoint the factors responsible for AD pathogenesis and develop
therapeutics against them.
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